<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006885.pub2" GROUP_ID="PROSTATE" ID="298707072320592083" MERGED_FROM="" MODIFIED="2011-05-02 16:04:27 +0200" MODIFIED_BY="James Tacklind" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.1" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-05-02 16:04:27 +0200" MODIFIED_BY="James Tacklind">
<TITLE MODIFIED="2008-12-22 12:06:25 -0600" MODIFIED_BY="James Tacklind">Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer</TITLE>
<CONTACT MODIFIED="2011-05-02 16:04:27 +0200" MODIFIED_BY="James Tacklind"><PERSON ID="DCD4D19082E26AA2017A33F2613E51A1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Zhong Jin</FIRST_NAME><LAST_NAME>Yue</LAST_NAME><EMAIL_1>yuezhongjin@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Second Hospital of Lanzhou University</ORGANISATION><ADDRESS_1>No. 82, Cui Ying Men Street</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730030</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>13919059669</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-05-02 16:04:27 +0200" MODIFIED_BY="James Tacklind"><PERSON ID="F3C89D4F82E26AA20093068A1FDF7A7B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Pan Feng</FIRST_NAME><LAST_NAME>Shang</LAST_NAME><EMAIL_1>shangpanfeng@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Second Hospital of Lanzhou University</ORGANISATION><ADDRESS_1>No. 82, Cui Ying Men Street</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730030</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY></ADDRESS></PERSON><PERSON ID="D2C07C8E82E26AA20046B3728137BA7B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Joey</FIRST_NAME><LAST_NAME>Kwong</LAST_NAME><POSITION>Managing Editor, Cochrane Heart Group</POSITION><EMAIL_1>joey.kwong@lshtm.ac.uk</EMAIL_1><EMAIL_2>cochrane.heart@lshtm.ac.uk</EMAIL_2><ADDRESS><DEPARTMENT>Department of Non-Communicable Disease Epidemiology</DEPARTMENT><ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION><ADDRESS_1>Keppel Street</ADDRESS_1><CITY>London</CITY><ZIP>WC1E 7HT</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 20 7927 2086</PHONE_1><FAX_1>+44 20 7927 2286</FAX_1></ADDRESS></PERSON><PERSON ID="DCD4D02982E26AA2017A33F21A56C994" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Zhi Ping</FIRST_NAME><LAST_NAME>Wang</LAST_NAME><EMAIL_1>erywzp@lzu.edu.cn</EMAIL_1><ADDRESS><DEPARTMENT>Institute of Urology</DEPARTMENT><ORGANISATION>Second Hospital of Lanzhou University</ORGANISATION><ADDRESS_1>No. 82, Cui Ying Men Street</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730030</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 1 38 9313 1697</PHONE_1><FAX_1>+86 0 93 1894 2498</FAX_1></ADDRESS></PERSON><PERSON ID="F9F5016182E26AA201E74FE90425DF07" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jinhui</FIRST_NAME><LAST_NAME>Tian</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>tjh996@163.com</EMAIL_1><EMAIL_2>tianjh@lzu.edu.cn</EMAIL_2><MOBILE_PHONE>+3619342312</MOBILE_PHONE><ADDRESS><DEPARTMENT>Evidence-Based Medicine Center, School of Basic Medical Sciences</DEPARTMENT><ORGANISATION>Lanzhou University</ORGANISATION><ADDRESS_1>No. 199, Donggang West Road</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730000</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 93 1891 5076</PHONE_1><PHONE_2>+86 93 1891 5076</PHONE_2><FAX_1>+86 93 1891 5076</FAX_1></ADDRESS></PERSON><PERSON ID="9D0C14B782E26AA200ACC39927E8375D" ROLE="AUTHOR"><PREFIX>Mr</PREFIX><FIRST_NAME>Lei</FIRST_NAME><LAST_NAME>Jiang</LAST_NAME><POSITION>Teacher</POSITION><EMAIL_1>goodjianglei@163.com</EMAIL_1><MOBILE_PHONE>13099167864</MOBILE_PHONE><ADDRESS><DEPARTMENT>Evidence-Based Medicine Center, School of Basic Medical Sciences</DEPARTMENT><ORGANISATION>Lanzhou University</ORGANISATION><ADDRESS_1>No. 199, Donggang West Road</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730000</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 136 1934 4961</PHONE_1><PHONE_2>+86 93 1891 5076</PHONE_2></ADDRESS></PERSON><PERSON ID="77967973666680461929090922103000" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>KeHu</FIRST_NAME><LAST_NAME>Yang</LAST_NAME><POSITION>Dean</POSITION><EMAIL_1>yangkh@lzu.edu.cn</EMAIL_1><EMAIL_2>Yangkh2006@163.com</EMAIL_2><MOBILE_PHONE>+86 13893117077</MOBILE_PHONE><ADDRESS><DEPARTMENT>Evidence-Based Medicine Center, School of Basic Medical Sciences</DEPARTMENT><ORGANISATION>Lanzhou University</ORGANISATION><ADDRESS_1>No. 199, Donggang West Road</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730000</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>+86 93 1981 2767</PHONE_1><PHONE_2>+13893117077</PHONE_2><FAX_1>+86 093 1891 5076</FAX_1></ADDRESS></PERSON><PERSON ID="DCD4D19082E26AA2017A33F2613E51A1" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Zhong Jin</FIRST_NAME><LAST_NAME>Yue</LAST_NAME><EMAIL_1>yuezhongjin@yahoo.com.cn</EMAIL_1><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Second Hospital of Lanzhou University</ORGANISATION><ADDRESS_1>No. 82, Cui Ying Men Street</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730030</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>13919059669</PHONE_1></ADDRESS></PERSON><PERSON ID="DCD4CB2882E26AA2017A33F24515466D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Jun Qiang</FIRST_NAME><LAST_NAME>Tian</LAST_NAME><EMAIL_1>tianjunq03@lzu.cn</EMAIL_1><ADDRESS><DEPARTMENT>Evidence-Based Medicine Center, School of Basic Medical Sciences</DEPARTMENT><ORGANISATION>Lanzhou University</ORGANISATION><ADDRESS_1>No. 199, Donggang West Road</ADDRESS_1><CITY>Lanzhou City</CITY><ZIP>730000</ZIP><REGION>Gansu</REGION><COUNTRY CODE="CN">China</COUNTRY><PHONE_1>13919126967</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-05-02 09:01:26 -0500" MODIFIED_BY="James Tacklind">
<UP_TO_DATE>
<DATE DAY="1" MONTH="4" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="4" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="16" MONTH="3" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="5" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2011"/>
</DATES>
<WHATS_NEW MODIFIED="2011-05-02 08:26:36 -0500" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-02 08:26:36 -0500" MODIFIED_BY="James Tacklind">
<DATE DAY="2" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>As per comments received from the Cochrane Editorial Unit, the review has been slightly amended to reflect recommendations on abstract and plain language summary title. Some minor edits to other sections of the review have been performed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-05-02 08:26:22 -0500" MODIFIED_BY="James Tacklind">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-02 08:26:22 -0500" MODIFIED_BY="James Tacklind">
<DATE DAY="2" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-10-06 10:39:10 -0500" MODIFIED_BY="James Tacklind">
<INTERNAL_SOURCES MODIFIED="2009-03-07 03:43:39 -0600" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2009-03-07 03:33:51 -0600" MODIFIED_BY="[Empty name]">
<NAME>Institute of Urology, The Second Hospital of Lanzhou University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-03-07 03:34:37 -0600" MODIFIED_BY="[Empty name]">
<NAME>The Centre of Evidence Based Medicine of Lanzhou University</NAME>
<COUNTRY CODE="CN">China</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-05-02 08:54:40 -0500" MODIFIED_BY="James Tacklind">
<SUMMARY MODIFIED="2011-05-01 22:24:28 -0500" MODIFIED_BY="Joey Kwong">
<TITLE MODIFIED="2011-05-01 22:24:18 -0500" MODIFIED_BY="Joey Kwong">Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer</TITLE>
<SUMMARY_BODY MODIFIED="2011-05-01 22:24:28 -0500" MODIFIED_BY="Joey Kwong">
<P>Transurethral resection (TUR) is the usual treatment method for patients who, when examined with a cystoscope, are found to have abnormal growths on the urothelium (stage Ta) and/or in the lamina propria (stage T1). However post-operation tumour recurrence is a major clinical problem. Intravesical Bacillus Calmette-Guérin or epirubicin following surgery are therefore often used to try to prevent the cancer recurrence. This review found that intravesical Bacillus Calmette-Guérin is more efficacious than epirubicin to prevent cancer recurrence. However, Bacillus Calmette-Guérin appears to induce greater local and systemic adverse effects than epirubicin.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-05-02 08:54:40 -0500" MODIFIED_BY="James Tacklind">
<ABS_BACKGROUND MODIFIED="2011-03-14 09:49:05 -0500" MODIFIED_BY="James Tacklind">
<P>Bladder cancer accounts for approximately 4.4% of adult malignancies, and approximately 80% of bladder cancer presents initially as transitional cell carcinoma that is confined to the urothelium (stage Ta) or lamina propria (stage T1). Intravesical administration of Bacillus Calmette-Guérin (BCG) and epirubicin (EPI) has been proven to reduce tumour recurrence and prevent or delay progression to muscle invasion and metastases. However, comparison of the effectiveness and safety of intravesical BCG and EPI in bladder cancer has yet to be explored.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-03-14 09:49:43 -0500" MODIFIED_BY="James Tacklind">
<P>To compare the effectiveness and safety of BCG with EPI in the treatment of Ta and T1 bladder cancer.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2011-05-01 22:24:04 -0500" MODIFIED_BY="Joey Kwong">
<P>A comprehensive search of MEDLINE (January 1966 to April 2010), EMBASE (January 1980 to April 2010), the Cochrane Library(Issue 5, 2010), Health Services Technology, Administration, and Research (HealthSTAR), and CancerLit etc, was performed, and handsearching of relevant journals was undertaken.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-05-01 22:21:45 -0500" MODIFIED_BY="Joey Kwong">
<P>All randomised or quasi-randomised trials (in which allocation was obtained by alternation - e.g. alternate medical records, date of birth, or other predictable methods) in patients with Ta or T1 bladder cancer that compared intravesical BCG with EPI were included. No language restrictions were applied.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-07-16 15:03:53 -0500" MODIFIED_BY="James Tacklind">
<P>Trial eligibility, methodological quality and data extraction were assessed independently by two reviewers. We compared dichotomous outcomes (frequency of tumour recurrence, progressive disease by stage, mortality, distant metastases, local and systemic adverse effects, treatment delayed or stopped due to adverse effects) using risk ratios (RR) with 95% confidence intervals (CI).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-05-02 08:54:40 -0500" MODIFIED_BY="James Tacklind">
<P>Five trials of 1,111 participants were included in this review. 549 patients were treated with BCG and 562 with EPI. Baseline characteristics of included participants were similar amongst the five trials. We found that nearly none of the included studies described clearly the method of sequence generation, allocation concealment and blinding. Only two trials of 769 patients had sufficient data for us to analyze both disease-specific and overall mortality. There was no significant difference for mortality between BCG and EPI (overall mortality: RR 0.86, 95% CI 0.71 to 1.04, P = 0.12; disease-specific mortality: RR 0.94, 95% CI 0.23 to 0.80, P = 0.93). In four studies reporting local adverse effects, BCG was associated with significantly more drug-induced cystitis (BCG, 54.1% (232/429); EPI, 31.7% (140/441)) and haematuria (BCG, 30.8% (132/429); EPI, 16.1% (71/440)). Similarly, in three studies reporting systemic adverse effects, BCG had significantly higher toxicity than the EPI (34.8% (134/385) versus 1.3% (5/393), respectively).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-07-19 09:25:21 -0500" MODIFIED_BY="James Tacklind">
<P>The data from the present meta-analysis indicate that intravesical BCG treatment is more efficacious than EPI in reducing tumour recurrence for Ta and T1 bladder cancer. However, BCG appears to be associated with a higher incidence of adverse effects, such as drug-induced cystitis, haematuria and systemic toxicity, than EPI. The overall quality of the evidence is rather low. Well-designed, high quality randomised controlled trials with good allocation concealment are required.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-05-02 08:36:37 -0500" MODIFIED_BY="James Tacklind">
<BACKGROUND MODIFIED="2011-01-27 20:08:45 -0600" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-01-27 20:08:45 -0600" MODIFIED_BY="[Empty name]">
<P>Bladder cancer accounts for approximately 4.4% of adult malignancies, and more than 90% of cases originate in the transitional epithelial cells (transitional cell carcinoma) (<LINK REF="REF-Oosterlinck-2002" TYPE="REFERENCE">Oosterlinck 2002</LINK>; <LINK REF="REF-Parkin-2002" TYPE="REFERENCE">Parkin 2002</LINK>). Cigarette smoking is recognized as a major risk factor of bladder cancer and accounts for about 50% of cases in developed countries (<LINK REF="REF-Alberg-2007" TYPE="REFERENCE">Alberg 2007</LINK>;<B> </B>
<LINK REF="REF-Jankovic-2007" TYPE="REFERENCE">Jankovic 2007</LINK>). Bladder cancer is approximately three times more common in men than women (<LINK REF="REF-Parkin-2002" TYPE="REFERENCE">Parkin 2002</LINK>). The worldwide incidence and mortality rates of bladder cancer have increased steadily from 1993 to 2002 (<LINK REF="REF-Parkin-2002" TYPE="REFERENCE">Parkin 2002</LINK>). In 2002 there were 356,557 newly diagnosed bladder cancer cases and 145,009 related deaths (<LINK REF="REF-Ferlay-2004" TYPE="REFERENCE">Ferlay 2004</LINK>). Approximately 80% of bladder cancer presents initially as transitional cell carcinoma that is confined to the urothelium (stage Ta) or lamina propria (stage T1) (<LINK REF="STD-Uekado-1994" TYPE="STUDY">Uekado 1994</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-10-06 11:06:09 -0500" MODIFIED_BY="James Tacklind">
<P>Transurethral resection is the primary mode of therapy for Ta and T1 bladder cancer (<LINK REF="REF-van-der-Meijden-2006" TYPE="REFERENCE">van der Meijden 2006</LINK>; <LINK REF="REF-Parekh-2006" TYPE="REFERENCE">Parekh 2006</LINK>). However, post-operative tumour recurrence is a major clinical problem, with a rate of 50% to 70% within 5 years of surgery (<LINK REF="REF-Herr-1997" TYPE="REFERENCE">Herr 1997</LINK>).</P>
<P>The mechanisms of development of post-operative tumour recurrence include: 1) residual tumour caused by incomplete resection; 2) subsequent implantation of floating circulating tumour cells at traumatised sites in the bladder; 3) new tumour occurrences due to the highly aggressive nature of bladder cancer; and finally, 4) true recurrences at sites of urothelial instability (dysplasia, hyperplasia and atypia) (<LINK REF="REF-Eleanor-2006" TYPE="REFERENCE">Eleanor 2006</LINK>). Approximately 10% to 15% of superficial bladder cancer develops into muscle-invasive disease after initial transurethral resection (<LINK REF="REF-Lutzeyer-1982" TYPE="REFERENCE">Lutzeyer 1982</LINK>). In stage T1 bladder cancer these is further significant potential for progression and metastasis. Therefore, intravesical chemotherapy or immunotherapy are used in all cases following transurethral resection with the aim to eradicate existing disease, inhibit tumour recurrence, prevent tumour progression, and prolong overall survival (<LINK REF="STD-Whelan-2007" TYPE="STUDY">Whelan 2007</LINK>).</P>
<P>The intravesical chemotherapeutic drugs used following transurethral resection consist of mitomycin, doxorubicin, epirubicin (EPI), and thiotepa. EPI belongs to the family of anthracyclines and it was developed to reduce toxicity while maintaining antitumourigenic effects similar to those of doxorubicin and mitomycin C (<LINK REF="REF-Cersosimo-1986" TYPE="REFERENCE">Cersosimo 1986</LINK>; <LINK REF="REF-Da-Silva-1992" TYPE="REFERENCE">Da Silva 1992</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-01-29 09:04:23 -0600" MODIFIED_BY="[Empty name]">
<P>EPI exerts its antitumour effects by interfering with the synthesis and function of DNA (deoxyribonucleic acid). It is associated with a relatively low incidence of adverse effects in patients with Ta or T1 bladder cancer (<LINK REF="REF-Calais-da-Silva-1988" TYPE="REFERENCE">Calais da Silva 1988</LINK>; <LINK REF="REF-Popert-1994" TYPE="REFERENCE">Popert 1994</LINK>; <LINK REF="REF-Eto-1994" TYPE="REFERENCE">Eto 1994</LINK>; <LINK REF="REF-Mitsumori-2004" TYPE="REFERENCE">Mitsumori 2004</LINK>). Intravesical immunotherapy is predominantly done with BCG, and first used by Morales in 1976 (<LINK REF="REF-Morales-1976" TYPE="REFERENCE">Morales 1976</LINK>). The viable avirulent attenuated tuberculosis vaccine, BCG, is recognized as a nonspecific immune stimulant. Although the precise mechanism has not been adequately clarified, BCG may activate macrophages, T lymphocytes, B lymphocytes, and natural killer cells (NK), thus augmenting the host's response to tumour surveillance (<LINK REF="REF-Naoe-2007" TYPE="REFERENCE">Naoe 2007</LINK>; <LINK REF="REF-Morgan-2002" TYPE="REFERENCE">Morgan 2002</LINK>; <LINK REF="REF-Lebret-2000" TYPE="REFERENCE">Lebret 2000</LINK>; <LINK REF="REF-Kamat-2000" TYPE="REFERENCE">Kamat 2000</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-10-06 11:08:55 -0500" MODIFIED_BY="James Tacklind">
<P>The data from two systematic reviews indicated that BCG was significantly more effective than mitomycin C and transurethral resection in the prophylaxis of Ta and T1 bladder cancer (<LINK REF="STD-Shelley-2003" TYPE="STUDY">Shelley 2003</LINK>; <LINK REF="REF-Shelley-2000" TYPE="REFERENCE">Shelley 2000</LINK>), but comparison of intravesical BCG and EPI in bladder cancer has yet to be explored. Our review was conducted to compare the efficacy and safety of intravesical BCG with EPI to Ta and T1 bladder cancer from published randomised controlled trials.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-01-29 09:04:58 -0600" MODIFIED_BY="[Empty name]">
<P>To compare the effectiveness and safety of BCG with EPI in the treatment of Ta and T1 bladder cancer.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-05-01 22:25:14 -0500" MODIFIED_BY="Joey Kwong">
<SELECTION_CRITERIA MODIFIED="2011-04-30 09:06:53 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-04-30 09:06:53 -0500" MODIFIED_BY="[Empty name]">
<P>All randomised or quasi-randomised trials (in which allocation was obtained by alternation - e.g., alternate medical records, date of birth, or other predictable methods) in patients with Ta<SUB> </SUB>or T1 bladder cancer that compared intravesical BCG with EPI, were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-04-30 09:06:50 -0500" MODIFIED_BY="[Empty name]">
<P>Adults (&gt; 18 years) with Ta and T1 bladder cancer treated with transurethral resection.</P>
<P>Patients with CIS (stage Tis) of the bladder were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-01-29 09:06:05 -0600" MODIFIED_BY="[Empty name]">
<P>Intravesical therapy with BCG of any strain or schedule compared to EPI at any dose or schedule.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-03-14 10:00:41 -0500" MODIFIED_BY="James Tacklind">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-03-14 10:00:41 -0500" MODIFIED_BY="James Tacklind">
<OL>
<LI>Frequency of tumour recurrence (relapse)</LI>
<LI>Disease progression by stage (&#8805; stage T2)</LI>
<LI>Mortality (overall and disease-specific)</LI>
<LI>Distant metastases</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-01-29 09:07:23 -0600" MODIFIED_BY="[Empty name]">
<OL>
<LI>Local adverse effects (drug-induced cystitis, haematuria, etc)</LI>
<LI>Systemic adverse effects (fever with or without chills, influenza-like syndrome, nausea, vomiting, anorexia, BCG lung infection, skin rash, general malaise)</LI>
<LI>Delayed or terminated treatment due to adverse effects</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2011-05-01 22:25:14 -0500" MODIFIED_BY="Joey Kwong">
<ELECTRONIC_SEARCHES MODIFIED="2011-05-01 22:25:14 -0500" MODIFIED_BY="Joey Kwong">
<P>A. The Cochrane Prostatic Diseases and Urologic Cancers Group specialised register and the Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I> (Issue 5, 2010) were searched using the following terms.</P>
<OL>
<LI>MeSH descriptor urinary bladder neoplasms explode all trees</LI>
<LI>urinary bladder neoplasm*:ti,ab,kw</LI>
<LI>bladder tumour*:ti,ab,kw</LI>
<LI>urinary bladder cancer*:ti,ab,kw</LI>
<LI>OR/1-4</LI>
<LI>MeSH descriptor epirubicin explode all trees</LI>
<LI>epirubicin:ti,ab,kw</LI>
<LI>epiadriamycin:ti,ab,kw</LI>
<LI>epidoxorubicin:ti,ab,kw</LI>
<LI>epi doxorubicin:ti,ab,kw</LI>
<LI>epi adriamycin:ti,ab,kw</LI>
<LI>OR/6-11</LI>
<LI>MeSH descriptor BCG vaccine explode all trees</LI>
<LI>bacillus calmette guerin:ti,ab,kw</LI>
<LI>bcg:ti,ab,kw</LI>
<LI>OR/13-15</LI>
<LI>(5 AND 12 AND 16)</LI>
</OL>
<P>B. MEDLINE (January 1966 to April 2010) using the optimally sensitive strategy developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>) with a specific search strategy developed with input from the Cochrane Renal Groups' Trial Search Co-ordinator.</P>
<OL>
<LI>randomised controlled trial.pt</LI>
<LI>controlled clinical trial.pt</LI>
<LI>randomised controlled trials/</LI>
<LI>random allocation/</LI>
<LI>double blind method/</LI>
<LI>single-blind method/</LI>
<LI>or/1-6</LI>
<LI>(animal not human).sh.</LI>
<LI>7 not 8</LI>
<LI>clinical trial.pt.</LI>
<LI>exp clinical trials/</LI>
<LI>(clin$adj25 trial$).tw.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</LI>
<LI>placebos/</LI>
<LI>placebo$.tw.</LI>
<LI>random$.tw.</LI>
<LI>research design/</LI>
<LI>or/10-17</LI>
<LI>18 not 8</LI>
<LI>19 not 9</LI>
<LI>comparative study/</LI>
<LI>exp evaluation studies/</LI>
<LI>follow up studies/</LI>
<LI>prospective studies/</LI>
<LI>(control$ or prospectiv$ or volunteer$).tw</LI>
<LI>or/2-25</LI>
<LI>26 not 8</LI>
<LI>26 not (9 or 20)</LI>
<LI>9 or 20 or 28</LI>
<LI>exp urinary bladder neoplasms/</LI>
<LI>urinary bladder neoplasm$.tw</LI>
<LI>bladder tumour$.tw</LI>
<LI>urinary bladder cancer$.tw</LI>
<LI>or/30-33</LI>
<LI>exp epirubicin/</LI>
<LI>epirubicin.tw</LI>
<LI>epiadriamycin.tw</LI>
<LI>epidoxorubicin.tw</LI>
<LI>epi doxorubicin.tw</LI>
<LI>epi adriamycin.tw</LI>
<LI>or/35-40</LI>
<LI>exp BCG vaccine/</LI>
<LI>bacillus calmette guerin.tw</LI>
<LI>bcg.tw</LI>
<LI>or/42-44</LI>
<LI>29 and 34 and 41 and 45</LI>
</OL>
<P>C. EMBASE (January 1980 to April 2010) using a search strategy adapted from that developed for the Cochrane Collaboration for the identification of RCTs (<LINK REF="REF-Lefebvre-1996" TYPE="REFERENCE">Lefebvre 1996</LINK>) together with a specific search strategy developed with input from The Cochrane Prostatic Diseases and Urologic Cancers Group Trials Search Co-ordinator.</P>
<OL>
<LI>exp clinical trial/</LI>
<LI>comparative study/</LI>
<LI>drug comparison/</LI>
<LI>major clinical study/</LI>
<LI>randomization/</LI>
<LI>crossover procedure/</LI>
<LI>double blind procedure/</LI>
<LI>single blind procedure/</LI>
<LI>placebo/</LI>
<LI>prospective study/</LI>
<LI>((clinical or controlled or comparative or placebo or prospective or randomi#ed) adj3 (trial or study)).ti,ab.</LI>
<LI>(random$ adj7 (allocat$ or allot$ or assign$ or basis$ or divid$ or order$)).ti,ab.</LI>
<LI>((singl$ or doubl$ or trebl$ or tripl$) adj7 (blind$ or mask$)).ti,ab.</LI>
<LI>(cross?over$ or (cross adj1 over$)).ti,ab.</LI>
<LI>((allocat$ or allot$ or assign$ or divid$) adj3 (condition$ or experiment$ or intervention$ or treatment$ or therap$ or control$ or group$)).ti,ab.</LI>
<LI>or/1-10</LI>
<LI>or/11-15</LI>
<LI>(16 or 17)</LI>
<LI>exp bladder cancer/</LI>
<LI>urinary bladder neoplasm$.ti,ab.</LI>
<LI>bladder tumour$.ti,ab.</LI>
<LI>urinary bladder cancer$.ti,ab.</LI>
<LI>or/19-22</LI>
<LI>exp epirubicin/</LI>
<LI>epirubicin.ti,ab.</LI>
<LI>epiadriamycin.ti,ab.</LI>
<LI>epidoxorubicin.ti,ab.</LI>
<LI>epi doxorubicin.ti,ab.</LI>
<LI>epi adriamycin.ti,ab.</LI>
<LI>or/24-29</LI>
<LI>exp BCG vaccine/</LI>
<LI>bacillus calmette guerin.ti,ab</LI>
<LI>bcg.ti,ab</LI>
<LI>or/42-44</LI>
<LI>18 and 23 and 30 and 45</LI>
</OL>
<P>D. Other databases searched for trials included (The last search was carried out on 1 April 2010):</P>
<P>National Research Register;<BR/>Meta-register of Controlled Trials;<BR/>Medical Research Council Clinical Trials Directory;<BR/>The Cochrane Complimentary Medicine Field's register of trials;<BR/>WHO International Clinical Trials Registry Platform.</P>
<P>Health Services Technology, Administration, and Research (HealthSTAR)</P>
<P>CancerLit</P>
<P>No language restrictions were applied.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-01-29 09:08:44 -0600" MODIFIED_BY="[Empty name]">
<OL>
<LI>Reference lists of urology textbooks, review articles and relevant trials.</LI>
<LI>We contacted trial authors to identify unpublished papers, but did not contact pharmaceutical companies that produced the relevant products.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-03-14 10:00:48 -0500" MODIFIED_BY="James Tacklind">
<STUDY_SELECTION MODIFIED="2011-03-14 09:53:44 -0500" MODIFIED_BY="James Tacklind">
<P>The titles and abstracts identified from our searches were screened independently by PF Shang and JH Tian, and studies that were inapplicable were excluded. However, studies and reviews that might include relevant data or information on trials were retained initially. Two authors (PF Shang and ZJ Yue) independently assessed abstracts, and if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-03-14 09:55:06 -0500" MODIFIED_BY="James Tacklind">
<P>Data extraction was carried out independently by PF Shang and JQ Tian using standard data extraction forms. No trials were reported in non-English language journals. Where more than one publication of a trial existed, only the publication with the most complete data was included. Data in earliest versions of a trial were used for side effects, but long-term efficacy results come from latest versions. Any discrepancy between published versions was highlighted. We requested any missing data or relevant information by written requests to the trialists and authors. Disagreements were resolved in consultation with ZP Wang and KH Yang. One author (PF Shang) entered data into Review Manager 5 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-01-29 09:10:16 -0600" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of each trial, taking into account the issues of randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting and any other potential bias. Two authors (PF Shang, JQ Tian) assessed the studies independently according to the Cochrane Collaboration risk of bias assessment tools (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>). Discrepancies were resolved by discussion with KH Yang.</P>
<OL>
<LI>'Yes' - low risk of bias</LI>
<LI>'Unclear' - unclear risk of bias</LI>
<LI>'No' - high risk of bias</LI>
</OL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-03-14 10:00:48 -0500" MODIFIED_BY="James Tacklind">
<P>We analysed the data using Review Manager 5 and reported them according to Cochrane Collaboration criteria and the Cochrane Prostatic Diseases and Urologic Cancers Group guidelines. Dichotomous outcomes (e.g. frequency of tumour recurrence, disease progression by stage, mortality, distant metastases, local and systemic adverse effects, and delayed or terminated treatment due to adverse effects) were expressed as risk ratio (RR) with 95% confidence intervals (CI).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-01-29 09:10:55 -0600" MODIFIED_BY="[Empty name]">
<P>No cluster randomised or cross-over trials were included in our review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-01-29 09:11:15 -0600" MODIFIED_BY="[Empty name]">
<P>No missing data were found through contacting the authors of the included studies.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-10-06 13:08:52 -0500" MODIFIED_BY="James Tacklind">
<P>We initially checked for heterogeneity in the studies by reading the trial reports to see if we could identify any methodological differences between studies. I<SUP>2 </SUP>was used to assess heterogeneity.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-01-29 09:11:55 -0600" MODIFIED_BY="[Empty name]">
<P>We did not use a funnel plot to investigate the possibility of publication bias due to the small number of included studies. Instead we used a descriptive analysis to evaluate the possible reporting biases.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-01-29 09:12:12 -0600" MODIFIED_BY="[Empty name]">
<P>We used a fixed-effect model for outcomes without heterogeneity (I<SUP>2</SUP> &lt; 50%) and a random-effects model for outcomes with heterogeneity (I<SUP>2</SUP> &#8805; 50%) (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-01-27 20:44:57 -0600" MODIFIED_BY="[Empty name]">
<P>We performed subgroup analyses based on different BCG strains: Connaught BCG, Tice BCG and Pasteur BCG.</P>
<P>We did not perform subgroup analyses by different EPI doses because there were none.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-02-22 14:44:39 -0600" MODIFIED_BY="James Tacklind">
<P>For data with statistical heterogeneity (I<SUP>2 </SUP>&#8805; 50%), a sensitivity analysis was performed. We commented on the heterogeneity of the rest of the data.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-05-02 08:36:37 -0500" MODIFIED_BY="James Tacklind">
<STUDY_DESCRIPTION MODIFIED="2011-05-01 22:36:14 -0500" MODIFIED_BY="Joey Kwong">
<P>The size of the 5 included trials ranged between 94 and 560 patients (total 1,111). Together 549 patients were treated with BCG compared to 562 treated with EPI. All five included trials were randomised or quasi-randomised, prospective, controlled parallel studies and one were multicenter trial. All trials reported trial origination (Greece = 3; Europe = 1; Hong Kong, China= 2). Baseline characteristics were similar between the two groups in five trials. The mean age ranged from 65 to 70 years, and the median follow up length ranged from 32.9 to 110 months. The male to female ratio was 3.8:1 in the BCG group and 4.1:1 in the EPI group, respectively. The corresponding proportions of patients with Ta and T1 tumours were 62% and 38% in the BCG group, and 66% and 34% in the EPI group, respectively. The number of patients of grades 1, 2 and 3 were 173 (32%), 267 (50%), 97 (18%) in the BCG group, and 194 (35%), 274 (50%), 82 (15%) in the EPI group. For substantive description of studies please see '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' and '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>' tables.</P>
<SEARCH_RESULTS MODIFIED="2011-03-02 08:28:38 -0600" MODIFIED_BY="[Empty name]">
<P>The search strategy yielded 141 results.  Following screening of titles and abstracts, the full text of 15 studies were retrieved for further information. Of these, five studies with 1111 participants were included in our review ('<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>').  Further details of included studies are shown in '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Ten studies were excluded with the reasons for exclusion presented in '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-10-06 13:10:59 -0500" MODIFIED_BY="James Tacklind">
<P>Five trials were included in our review (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005;</LINK> <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>; <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>; <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>). Further particulars of these studies are included in '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>'. Five studies reported the frequency of tumour recurrence and disease progression by stage. Four studies reported distant metastases, local adverse effects, and delayed or terminated treatment due to adverse effects. Only two trials (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) included sufficient data to analyse disease-specific mortality and overall mortality.</P>
<P>
<LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> is a study from the European Organization for Research and Treatment of Cancer Genito-Urinary Group. The initial report published in 2001 compared the efficacy and adverse effects of BCG and EPI with a median follow up of 46.8 months; a subsequent report in 2010 revealed the long-term efficacy profiles (median follow up of 110 months).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-10-06 13:14:19 -0500" MODIFIED_BY="James Tacklind">
<P>
<LINK REF="STD-De-Reijke-2005a" TYPE="STUDY">De Reijke 2005a</LINK> was ineligible for inclusion because the trial included patients with CIS of the bladder. <LINK REF="STD-Merkle-1990" TYPE="STUDY">Merkle 1990</LINK> was in abstract form only and had insufficient data. Two trials (<LINK REF="STD-Iida-2009" TYPE="STUDY">Iida 2009</LINK>; <LINK REF="STD-Trinchieri-2005" TYPE="STUDY">Trinchieri 2005</LINK>) were non-randomised. The trial by Ali-El-Dein ( <LINK REF="STD-Ali_x002d_EI_x002d_Dein-2003" TYPE="STUDY">Ali-EI-Dein 2003</LINK>) was excluded because it is a non-synchronized controlled study. Four trials (<LINK REF="STD-Cai-2008" TYPE="STUDY">Cai 2008</LINK>; <LINK REF="STD-Bilen-2000" TYPE="STUDY">Bilen 2000;</LINK> <LINK REF="STD-Ali_x002d_El_x002d_Dein-1999" TYPE="STUDY">Ali-El-Dein 1999</LINK>; <LINK REF="STD-Erol-1994" TYPE="STUDY">Erol 1994</LINK>), comparing BCG with an alternating regime of BCG and EPI, were also excluded. The remaining reports were excluded as they were duplicate publications of the included trials. The details of the excluded studies are demonstrated in '<LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>'.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2011-05-01 22:38:58 -0500" MODIFIED_BY="Joey Kwong">
<P>The risk of bias of included studies was evaluated in several ways, such as randomisation, allocation concealment, blinding, completeness of outcome data, selective reporting, and any other potential bias. The risk of bias graph and risk of bias summary are displayed as <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>, respectively. Data were extracted by two authors (PF Shang, JQ Tian) independently. All included trials were randomised or quasi-randomised, controlled parallel studies. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> randomised patients by the minimization technique. Three trials (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>, <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>, <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>) were quasi-randomised by date of birth. The one other trial did not provide information on the randomisation method (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>). Our included studies were therefore judged to have a high risk of bias, and the overall methodological quality was low.</P>
<ALLOCATION MODIFIED="2010-10-06 13:21:03 -0500" MODIFIED_BY="James Tacklind">
<P>Only <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> used good allocation concealment methods (central randomization). The other four trials did not provide information on the allocation concealment, indicating an area of potential bias.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-07-01 08:30:56 -0500" MODIFIED_BY="[Empty name]">
<P>None of the included studies provided information on blinding.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-10-06 13:22:25 -0500" MODIFIED_BY="James Tacklind">
<P>Assessments were made for each main class of outcomes, where possible, and were based on the description of the outcome data, including attrition and exclusions from the analysis and their causes. Three trials (<LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK> <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) reported post-randomisation dropouts. These patients were excluded from the analysis. Therefore, these trials were considered at low risk for incomplete data bias. The other included trials (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005;</LINK> <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>) did not provide information on dropouts.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-10-06 13:24:09 -0500" MODIFIED_BY="James Tacklind">
<P>All included trials were designed primarily to compare the effectiveness and safety of BCG with EPI. Therefore, reporting bias introduced by the investigators was considered to be small. All five included trials reported expected outcomes.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-11-30 09:39:04 -0600" MODIFIED_BY="James Tacklind">
<P>We did not identify any other sources of bias in the included studies.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-05-02 08:36:37 -0500" MODIFIED_BY="James Tacklind">
<P>Of the 1,111 subjects in our included studies, 549 received BCG and 562 were treated with EPI. The results are reported as risk ratio (RR) with 95%confidence intervals (CI).</P>
<SUBSECTION>
<HEADING LEVEL="3">Frequency of tumour recurrence (relapse)</HEADING>
<P>BCG had significantly fewer incidents of tumour recurrence than did EPI (P &lt; 0.05).</P>
<P>Overall, 35.5% (195/549) of participants in the BCG group and 51.4% (289/562) in the EPI group had tumour recurrence (RR 0.69, 95% CI 0.60 to 0.79). There was no evidence of heterogeneity in the combined trials (I<SUP>2 </SUP>= 0%).</P>
<P>For the subgroup of patients treated with Connaught strain BCG, the comparison favoured BCG (RR 0.53, 95% CI 0.38 to 0.75). A subgroup analysis of two trials (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>, <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>), which treated patients with Pasteur strain BCG, found no significant difference between BCG and EPI (RR 0.78, 95% CI 0.56 to 1.10), and with no heterogeneity (I<SUP>2</SUP> = 0%). Another subgroup analysis of two studies (<LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) found Tice BCG to be superior to EPI in reducing tumour recurrence (RR 0.72, 95% CI 0.60 to 0.85; I<SUP>2</SUP> = 0%) ('<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Disease progression by stage (&#8805; stage T2)</HEADING>
<P>There was no significant difference for disease progression between BCG and EPI treatments (P = 0.19).</P>
<P>Forty-four participants (8.02%) progressed to T2 or greater disease in the BCG group and 58 (10.32%) in the EPI group (RR 0.78, 95% CI 0.54 to 1.13). There was no statistical heterogeneity (I<SUP>2 </SUP>= 0%).</P>
<P>However, subgroup analyses indicated no significant difference between BCG strains ('<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Mortality (Overall and disease-specific)</HEADING>
<P>There was no significant difference for mortality between BCG and EPI (overall mortality, P = 0.12; disease-specific mortality P = 0.93).</P>
<P>Only two trials (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) included sufficient data to analyse overall mortality and disease-specific mortality. They represented a total of 769 patients, 383 randomised to BCG and 386 to EPI. <LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK> stated a median follow up length of 61 months (range 3 to 127 months), <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> consisted of a median follow up of 110 months and a maximum follow up of 172 months.</P>
<SUBSECTION>
<HEADING LEVEL="4">Overall mortality</HEADING>
<P>The pooled results of <LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK> and <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> reported no significant difference in overall mortality between BCG and EPI (RR 0.86, 95% CI 0.71 to 1.04; I<SUP>2</SUP> = 47%) ('<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>').</P>
<P>Subgroup comparisons were performed and resulted in no significant differences for Connaught BCG (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>: RR 1.5, 95% CI 0.75 to 1.47), but <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> demonstrated that overall mortality was less frequent in the Tice BCG group compared with the EPI group (RR 0.79, 95% CI 0.62 to 0.99) ('<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Disease-specific mortality</HEADING>
<P>No significant difference was found between BCG and EPI (RR 0.94, 95% CI 0.23 to 3.80), but with considerable heterogeneity (I<SUP>2</SUP> = 82%) ('<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>'). This could be caused by different types of patients in the trials. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> included intermediate and high-risk patients, whereas <LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK> only included high-risk patients. No significant differences were found between Connaught BCG (RR 1.95, 95% CI 0.81 to 4.69) (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>) or Tice BCG (RR 0.47, 95% CI 0.22 to 1.02) (<LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) with EPI.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Distant metastases</HEADING>
<P>There was no significant difference for distant metastases between BCG and EPI treatments (P = 0.29).</P>
<P>Data on distant metastases were available from four studies (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005;</LINK> <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>; <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>). The number of patients presenting at endpoint with distant metastases were 4.7% (23/487) in the BCG group and 6.3% (31/495) in the EPI group. No significant differences were found between Connaught BCG (RR 1.47, 95% CI 0.48 to 4.48), Pasteur BCG (RR 0.35, 95% CI 0.01 to 8.32) or Tice BCG (RR 0.64, 95% CI 0.35 to 1.17; I<SUP>2</SUP> = 0%) ('<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>') with EPI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Local side effects (drug-induced cystitis and haematuria)</HEADING>
<P>BCG had significantly more incidents of local side effects than did EPI (P &lt; 0.05).</P>
<P>Drug-induced cystitis and haematuria were reported as "local side effects" and were evaluated in four studies. Side effects were significantly higher in the BCG group (drug-induced cystitis, 54.1% versus 31.7%; haematuria 30.8% versus 16.1%, respectively).</P>
<SUBSECTION>
<HEADING LEVEL="4">Drug-induced cystitis</HEADING>
<P>While the comparison for cystitis favoured EPI (RR 1.92, 95% CI 1.38 to 2.65) ('<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>'), heterogeneity was still significant (I<SUP>2</SUP> = 71%). This could have been caused by different types of patients in the pooled trials: <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK> included only high risk patients; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> included intermediate and high risk patients; <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK> and <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK> included all-risk patients. In the Pasteur BCG subgroup, two studies (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>; <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>) demonstrated that incidence of drug-induced cystitis was significantly higher in the BCG group(RR 2.47, 95% CI 1.83 to 3.31; I<SUP>2</SUP> = 0%) ('<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>'). In the Tice BCG subgroup, cystitis were also higher in the BCG group (RR 1.50, 95% CI 1.16 to 1.93), with a small degree of heterogeneity (I<SUP>2</SUP> = 32%) ('<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>').</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Haematuria</HEADING>
<P>For haematuria, the comparison favoured EPI with no heterogeneity present (RR 1.90, 95% CI 1.47 to 2.45; I<SUP>2</SUP> = 0%; '<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>').</P>
<P>The participants were stratified into subgroups of BCG strains. In the Pasteur BCG group, two studies <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK> and <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK> demonstrated no significant difference between BCG and EPI (RR 1.66, 95% CI 0.94 to 2.94; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>). <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK> and <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> were pooled and result demonstrated that haematuria were significantly higher in the Tice BCG group (RR 1.97, 95% CI1.48 to 2.62; '<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>').</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Systemic adverse effects</HEADING>
<P>BCG had significantly more incidents of systemic adverse effects than did EPI (P &lt; 0.05).</P>
<P>Systematic adverse effects include fever with or without chills, influenza-like syndrome, nausea, vomiting, anorexia, BCG lung infection, skin rash and general malaise. Overall, three studies (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>; <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>) reported data on systemic side effects, which were significantly more frequent in the BCG group than the EPI group (34.8% versus 1.3%, respectively) (RR 0.53, 95% CI 2.25 to 143.91; '<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>'). However, there was significant heterogeneity between trials (I<SUP>2</SUP> = 79%) due to the frequency of BCG administration. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> reported a total of 27 administrative episodes of intravesical BCG, compared to those reported by <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK> (14 or 18 episodes) and <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK> (16 episodes).</P>
<P>For participants treated with Pasteur BCG (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>), incidence of systemic adverse effects was significantly higher in the BCG group (RR 13.51, 95% CI 3.34 to 54.68). In another subgroup of Tice BCG (<LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>; <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>), systemic adverse effects were more frequent in the BCG group (RR 28.02, 95% CI 0.21 to 3677.42), but with significant heterogeneity (I<SUP>2</SUP> = 90%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Delayed or terminated treatment due to adverse effects</HEADING>
<P>There was no significant difference for delay or terminated treatment due to adverse effects between BCG and EPI treatments (P = 0.82).</P>
<P>Treatment delayed or stopped was reported in four studies, with 9.28% (40/431) of participants in the BCG group and 7.48% (33/441) in the EPI group reporting this outcome. The pooled analysis demonstrated no significant difference between BCG and EPI (RR 0.91, 95% CI 0.41 to 2.04), but with considerable heterogeneity (I<SUP>2</SUP> = 53%) ('<LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>'). This could have been caused by heterogeneous participants. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> included intermediate and high-risk patients. <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK> included high-risk patients. <LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK> and <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>, which included all-risk patients, showed no significant difference between treatments (RR 0.64, 95% CI 0.24 to 1.69), and no heterogeneity (I<SUP>2</SUP> = 0%).</P>
<P>Subgroup analysis were performed and resulted in no significant difference between Pasteur BCG and EPI (RR 0.64, 95% CI 0.24 to 1.69; I<SUP>2</SUP> = 0%). A similar insignificant difference was observed in the subgroup of Tice BCG (RR 1.06, 95% CI 0.26 to 4.32; I<SUP>2</SUP> = 75%).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-04-30 04:16:39 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-04-30 04:16:39 -0500" MODIFIED_BY="[Empty name]">
<P>This systematic review assessed the evidence from five randomised and quasi-randomised controlled trials on the efficacy and safety of intravesical BCG versus EPI. In 1992, the European Organization for Research and Treatment of Cancer (EORTC) launched a trial to compare the efficacy and side effects of intravesical instillations of BCG and EPI in patients with intermediate and high risk Ta, T1 bladder cancer. The first results, dealing mainly with recurrence and side effects, were published in 2001. A subsequent report in 2010 presents the final long-term efficacy results (<LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>). Our results indicate that BCG was superior to EPI in reducing tumour recurrence, but local and systemic adverse effects were significantly more frequent in the BCG group. Although the pooled analysis demonstrated that disease progression was less frequent in the BCG group compared with the EPI group, the difference was of no statistical significance. This result may reflect the limited data available, and thus more and larger trials are needed. Both BCG and EPI were equivalent in overall mortality, disease-specific mortality as well as in distant metastases. Adverse events, such as drug-induced cystitis, haematuria and systemic adverse effects, were significantly more frequent in the BCG group compared to the EPI group. One study found "delayed or terminated treatment" was significantly more common in the BCG group (<LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>). But, three studies showed "delayed or terminated treatment" was less frequent in the BCG group compared to the EPI group, and was not statistically significant (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>; <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>; <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>). However, there was significant heterogeneity between these trials. By excluding <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> in our sensitivity analysis, we found no significant difference between them. A random-effects model was used for reporting disease-specific mortality, drug-induced cystitis, systemic adverse effects, and 'delayed or terminated treatment'. All of these were associated with considerable heterogeneity (I<SUP>2</SUP> &gt; 50%) and therefore likely to be prone to bias.</P>
<P>Unfortunately, patient selection was heterogeneous. Two trials included all risk categories (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>; <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>). <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> included Intermediate and high-risk participants. In the other two trials only high-risk patients were treated (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>; <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>), although tumour grade affected independently the rates of recurrence and progression after resecting superficial bladder cancer. However, without individual patient data, the effect on the outcome of tumour grade cannot be pooled. Moreover, there are clear differences in treatment schedules and doses for intravesical BCG and EPI. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> used intravesical BCG (Tice strain) or EPI (50 mg) on thrice weekly maintenance instillations of 3, 6, 12, 18, 24, 30 and 36 months, following 6 weekly initial inductions; this treatment schedule was significantly more frequently than those used in other included studies. We suspect that treatment schedule and frequency will influence therapy efficacy and side effects (<LINK REF="REF-Koga-2004" TYPE="REFERENCE">Koga 2004</LINK>; <LINK REF="REF-Wilson-2010" TYPE="REFERENCE">Wilson 2010</LINK>). Finally, the follow-up period of the included trials also varied and likely affected outcomes, especially for mortality rates. <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK>, with a median follow up of 110 months, was significantly longer than the other studies. Thus, we need to be careful with conclusions based on this meta-analysis because patient selection, maintenance schedules, and follow up, were heterogeneous.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-01-27 20:30:53 -0600" MODIFIED_BY="[Empty name]">
<P>The search we undertook was comprehensive and likely identified all relevant research. A number of trials compared the effectiveness and safety of BCG with EPI to bladder cancer treatments. However, they were excluded because they were not RCTs. Most of the included trials addressed recurrence and progression of superficial bladder cancer, but data regarding mortality were limited. Only two studies provided data for overall and disease-specific mortality. Thus, this systematic review provides the currently available information regarding reducing tumour recurrence, local and systemic side effects of intravesical BCG versus EPI following TUR for Ta and T1 bladder cancer. However, it is clear that more trials assessing overall and disease-specific mortality with follow-up longer than 5 years are required. Furthermore, further trials is required to understand progressive disease by stage, mortality, distant metastases and delayed or terminated treatment due to adverse effects between the two groups. Future trials should adhere to recommendations to enhance the conduct, reporting, and evaluation of RCTs (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>).</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-01-27 20:31:46 -0600" MODIFIED_BY="[Empty name]">
<P>Five studies were described as randomised, but only <LINK REF="STD-Sylvester-2010" TYPE="STUDY">Sylvester 2010</LINK> randomised patients by the minimization technique and used a good allocation concealment method. Three trials (<LINK REF="STD-Melekos-1993" TYPE="STUDY">Melekos 1993</LINK>, <LINK REF="STD-Melekos-1996a" TYPE="STUDY">Melekos 1996a</LINK>, <LINK REF="STD-Melekos-1996b" TYPE="STUDY">Melekos 1996b</LINK>) randomised patients according to dates of birth (quasi-randomised). The other one trial did not provide details on the randomisation method (<LINK REF="STD-Cheng-2005" TYPE="STUDY">Cheng 2005</LINK>). All included trials did not report methods of blinding and analysis not by intention-to-treat (ITT). Therefore the overall quality of the evidence was rather low.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2011-01-27 20:32:11 -0600" MODIFIED_BY="[Empty name]">
<P>We performed a thorough search to source all available information, including published and unpublished data, without any language restrictions. Investigators were contacted to acquire additional information. Publication bias, however, should still be considered because all included studies were published in English, and not enough useful information was retrieved from the trial authors. For completeness, we invite readers to send us (for a future update) any published or unpublished studies that we may have missed, and that meet our inclusion criteria.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2011-01-27 20:37:59 -0600" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Sylvester-2005a" TYPE="STUDY">Sylvester 2005a</LINK> is a systematic review on BCG and chemotherapy (including epirubicin) in the treatment of patients with CIS of the bladder. A recent systematic review (<LINK REF="STD-Shelley-2010" TYPE="STUDY">Shelley 2010</LINK>) found that intravesical BCG had significantly fewer tumour recurrences than EPI in the management of superficial bladder cancers ( Ta, T1 or CIS), but with no significant differences in disease progression or overall survival. However, carcinoma in situ was not considered in our meta-analysis because CIS is potentially a highly malignant disease that can still be treated in the majority of cases with bladder instillations of BCG (<LINK REF="REF-Oosterlinck-2002" TYPE="REFERENCE">Oosterlinck 2002</LINK>). <LINK REF="STD-De-Reijke-2005a" TYPE="STUDY">De Reijke 2005a</LINK> compared BCG with EPI for carcinoma in situ of the bladder, and <LINK REF="STD-Ali_x002d_El_x002d_Dein-1999" TYPE="STUDY">Ali-El-Dein 1999</LINK> and <LINK REF="STD-Bilen-2000" TYPE="STUDY">Bilen 2000</LINK> compared BCG with an alternating regime of BCG and EPI; all three were excluded from our review.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2011-05-01 22:34:45 -0500" MODIFIED_BY="Joey Kwong">
<IMPLICATIONS_PRACTICE MODIFIED="2011-05-01 22:34:45 -0500" MODIFIED_BY="Joey Kwong">
<P>The evidence from the five RCTs clearly indicates that intravesical BCG is more effective than EPI in reducing tumour recurrence for Ta and T1 bladder cancer. BCG appears to induce greater drug-induced cystitis, haematuria and systemic adverse effects than EPI, and this needs to be taken into account when deciding management policy for Ta and T1 patients. We also conclude that the current evidence is clearly limited with too few trials and too few patients to determine overall mortality, disease-specific mortality, distant metastases, and treatment delayed or terminated between the two groups.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2011-01-27 20:35:15 -0600" MODIFIED_BY="[Empty name]">
<P>Future trials should be undertaken to compare BCG with EPI in Ta and T1 bladder cancer. These studies should provide data on progressive disease by stage, mortality, distant metastases, treatment delayed or stopped, and an economic evaluation. Additionally, such studies should be conducted using randomized treatment allocation, larger sample sizes, (which could help to determine clinically meaningful differences, beyond the play of chance, in patient-centered outcomes, including overall and disease-specific mortality), adequate allocation concealment, adequate blinding of assessors and subjects, completeness of follow up (ITT), and define the optimum dose and schedule for both BCG and EPI, when possible.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-06-26 20:10:10 -0500" MODIFIED_BY="[Empty name]">
<P>We thank James Tacklind, Managing Editor of the Cochrane Prostatic Diseases and Urologic Cancers Group.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-01-27 20:44:32 -0600" MODIFIED_BY="[Empty name]">
<P>We certify that we have no affiliations with or involvement in any organization or entity with a direct financial interest in the subject matter or materials discussed in this review (eg. employment, consultancy, stock ownership, honoraria, expert testimony).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-06-25 09:47:28 -0500" MODIFIED_BY="[Empty name]">
<P>Draft the protocol - PF Shang, KH Yang<BR/>Develop a search strategy - PF Shang, JH Tian<BR/>Search for trials - PF Shang, JH Tian<BR/>Obtain copies of trials - PF Shang, JH Tian, L Jiang<BR/>Select which trials to include - PF Shang , ZJ Yue<BR/>Extract data from trials - PF Shang, JQ Tian<BR/>Enter data into RevMan - PF Shang<BR/>Carry out the analysis -PF Shang, JQ Tian<BR/>Interpret the analysis - PF Shang, KH Yang, ZP Wang, J Kwong<BR/>Draft the final review - PF Shang, KH Yang, ZP Wang, J Kwong<BR/>Update the review - PF Shang, KH Yang</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-07-16 10:44:46 -0500" MODIFIED_BY="James Tacklind">
<P>Subgroups ('<LINK TAG="SUBGROUP_ANALYSIS" TYPE="SECTION">Subgroup analysis and investigation of heterogeneity</LINK>') were added after we began writing the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-02-09 10:50:44 -0600" MODIFIED_BY="James Tacklind">
<STUDIES MODIFIED="2010-10-06 11:02:55 -0500" MODIFIED_BY="James Tacklind">
<INCLUDED_STUDIES MODIFIED="2010-10-06 09:07:40 -0500" MODIFIED_BY="James Tacklind">
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2005" MODIFIED="2010-04-25 07:44:25 -0500" MODIFIED_BY="[Empty name]" NAME="Cheng 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-16 08:10:43 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, et al</AU>
<TI>Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer</TI>
<SO>International Journal of Urology</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>449-55</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:10:43 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:10:43 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15948743"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melekos-1993" MODIFIED="2010-05-08 11:31:30 -0500" MODIFIED_BY="[Empty name]" NAME="Melekos 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-01-16 08:10:35 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melekos MD, Chionis HS, Paranychianakis GS, Dauaher HH</AU>
<TI>Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer</TI>
<SO>Cancer</SO>
<YR>1993</YR>
<VL>72</VL>
<NO>5</NO>
<PG>1749-55</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:10:35 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:10:35 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8348504"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melekos-1996a" MODIFIED="2010-05-08 11:31:38 -0500" MODIFIED_BY="[Empty name]" NAME="Melekos 1996a" YEAR="1996">
<REFERENCE MODIFIED="2009-01-16 08:10:25 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melekos MD, Zarakovitis I, Dandinis K, Fokaefs E, Chionis H, Dauaher H, et al</AU>
<TI>BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospect</TI>
<SO>International Urology and Nephrology</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>4</NO>
<PG>499-509</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:10:25 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:10:25 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9119635"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melekos-1996b" MODIFIED="2010-05-08 11:31:43 -0500" MODIFIED_BY="[Empty name]" NAME="Melekos 1996b" YEAR="1996">
<REFERENCE MODIFIED="2009-01-16 08:10:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melekos MD, Zarakovitis IE, Fokaefs ED, Dandinis K, Chionis H, Bouropoulos C, et al</AU>
<TI>Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours</TI>
<SO>Oncology</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>4</NO>
<PG>281-8</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:10:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:10:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8692531"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sylvester-2010" MODIFIED="2010-10-06 09:07:40 -0500" MODIFIED_BY="James Tacklind" NAME="Sylvester 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-06 09:07:40 -0500" MODIFIED_BY="James Tacklind" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, et al</AU>
<TI>Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder</TI>
<SO>European Urology</SO>
<YR>2010</YR>
<VL>57</VL>
<NO>5</NO>
<PG>766-73</PG>
<IDENTIFIERS MODIFIED="2010-04-25 07:54:28 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-25 07:54:28 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20034729"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2010-06-25 09:45:26 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meijden AP, Brausi M, Zambon V, Kirkels W, De Balincourt C, Sylvester R, et al</AU>
<TI>Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European organization for research and treatment of cancer genito-urinary group randomized phase III trial</TI>
<SO>Journal of Urology</SO>
<YR>2001</YR>
<VL>166</VL>
<NO>2</NO>
<PG>476-81</PG>
<IDENTIFIERS MODIFIED="2010-05-08 12:26:58 -0500" MODIFIED_BY="Joey Kwong">
<IDENTIFIER MODIFIED="2010-05-08 12:26:58 -0500" MODIFIED_BY="Joey Kwong" TYPE="PUBMED" VALUE="11458050"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-10-06 11:02:55 -0500" MODIFIED_BY="James Tacklind">
<STUDY DATA_SOURCE="PUB" ID="STD-Addeo-2010" MODIFIED="2010-10-06 09:08:08 -0500" MODIFIED_BY="James Tacklind" NAME="Addeo 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-06 09:08:08 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addeo R, Caraglia M, Bellini S, Abbruzzese A, Vincenzi B, Montella L, MiragliuoloA, et al.</AU>
<TI>Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance</TI>
<SO>Journal of clinical oncology</SO>
<YR>2010</YR>
<VL>28</VL>
<NO>4</NO>
<PG>543-8</PG>
<IDENTIFIERS MODIFIED="2010-04-25 08:10:14 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-25 08:10:14 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19841330"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Akaza-1999" MODIFIED="2009-01-16 08:11:54 -0600" MODIFIED_BY="[Empty name]" NAME="Akaza 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-16 08:11:54 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akaza H, Kurth KH, Williams R, Hinotsu S, Jewett MAS, Naito K, et al</AU>
<TI>Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future direction</TI>
<SO>Urologic Oncology</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>4-5</NO>
<PG>121-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ali_x002d_EI_x002d_Dein-2003" MODIFIED="2009-03-20 13:56:20 -0500" MODIFIED_BY="James Tacklind" NAME="Ali-EI-Dein 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-20 13:56:20 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem el-HI, Nabeeh A, Ghoneim MA</AU>
<TI>Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index</TI>
<SO>British Journal of Urology International</SO>
<YR>2003</YR>
<VL>92</VL>
<NO>4</NO>
<PG>393-9</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:13:31 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:13:31 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12930428"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ali_x002d_El_x002d_Dein-1999" MODIFIED="2009-01-16 08:14:42 -0600" MODIFIED_BY="[Empty name]" NAME="Ali-El-Dein 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-16 08:14:42 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA</AU>
<TI>Sequential Bacillus Calmette-Guérin and epirubicin versus Bacillus Calmette-Guérin alone for superficial bladder tumors: a randomized prospective study</TI>
<SO>The Journal of Urology</SO>
<YR>1999</YR>
<VL>162</VL>
<NO>2</NO>
<PG>339-42</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:14:42 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:14:42 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10411034"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Badalament-1997" MODIFIED="2009-01-13 13:21:26 -0600" MODIFIED_BY="James Tacklind" NAME="Badalament 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-01-13 13:21:26 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badalament RA, Farah RN</AU>
<TI>Treatment of superficial bladder cancer with intravesical chemotherapy</TI>
<SO>Seminars in Surgical Oncology</SO>
<YR>1997</YR>
<VL>13</VL>
<NO>5</NO>
<PG>335-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barton-Grossman-1999" MODIFIED="2009-01-16 08:16:16 -0600" MODIFIED_BY="[Empty name]" NAME="Barton Grossman 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-01-16 08:16:16 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barton Grossman H, Debruyne FMJ, Akaza H, Aso Y, Kagawa S, Kakehi Y, et al</AU>
<TI>New treatment approaches for superficial and invasive bladder cancer</TI>
<SO>Urologic Oncology</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>4-5</NO>
<PG>183-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beltrami-2008" MODIFIED="2009-09-01 09:34:49 -0500" MODIFIED_BY="James Tacklind" NAME="Beltrami 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-01 09:34:49 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beltrami P, Ruggera L, Cazzoletti L, Schiavone D, Zattoni F</AU>
<TI>Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?</TI>
<SO>Prostate</SO>
<YR>2008</YR>
<VL>68</VL>
<NO>11</NO>
<PG>1241-7</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:31:22 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:31:22 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18484098"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bilen-2000" MODIFIED="2009-01-16 08:17:38 -0600" MODIFIED_BY="[Empty name]" NAME="Bilen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-16 08:17:38 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bilen CY, Ozen H, Aki FT, Aygun C, Ekici S, Kendi S</AU>
<TI>Clinical experience with BCG alone versus BCG plus epirubicin</TI>
<SO>International Journal of Urology</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>6</NO>
<PG>206-9</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:17:38 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:17:38 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10843451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bismarck-2004" MODIFIED="2009-03-20 13:56:53 -0500" MODIFIED_BY="James Tacklind" NAME="Bismarck 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-20 13:56:53 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bismarck E, Schmitz-Dräger BJ</AU>
<TI>Adjuvant and neoadjuvant therapy of urinary bladder carcinoma</TI>
<SO>Onkologe</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>Suppl 1</NO>
<PG>S14-5</PG>
<IDENTIFIERS MODIFIED="2009-03-01 03:27:16 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bohle-2005" MODIFIED="2009-03-20 13:57:14 -0500" MODIFIED_BY="James Tacklind" NAME="Bohle 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-20 13:57:14 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bohle A</AU>
<TI>Bacillus Calmette-Guérin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials: Editorial comment</TI>
<SO>International Brazilian Journal of Urology</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>5</NO>
<PG>507-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bono-1994" MODIFIED="2009-01-16 08:20:57 -0600" MODIFIED_BY="[Empty name]" NAME="Bono 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-01-16 08:20:57 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bono AV</AU>
<TI>Superficial bladder cancer: State of the art</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1994</YR>
<VL>35 Suppl</VL>
<PG>101-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bono-1995" MODIFIED="2009-10-06 03:09:44 -0500" MODIFIED_BY="[Empty name]" NAME="Bono 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-10-06 03:09:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bono AV, Lovisolo JA, Saredi G</AU>
<TI>Stage T1 grade 3 bladder cancer: Treatment and prognostic factors</TI>
<SO>Acta Urologica Italia</SO>
<YR>1995</YR>
<VL>9</VL>
<NO>5</NO>
<PG>229-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bono-2000" MODIFIED="2009-01-16 08:23:02 -0600" MODIFIED_BY="[Empty name]" NAME="Bono 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-01-16 08:23:02 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bono AV, Lovisolo JA, Saredi G</AU>
<TI>Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>4</NO>
<PG>478-83</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:23:02 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:23:02 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10765080"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borden-2003" MODIFIED="2009-01-16 08:24:58 -0600" MODIFIED_BY="[Empty name]" NAME="Borden 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-01-16 08:24:58 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borden LS Jr, Clark PE, Hall MC</AU>
<TI>Bladder cancer</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>3</NO>
<PG>227-33</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:24:58 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:24:58 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12778017"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borkowski-2002" MODIFIED="2009-03-20 13:59:22 -0500" MODIFIED_BY="James Tacklind" NAME="Borkowski 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-20 13:59:22 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borkowski A</AU>
<TI>Superficial bladder cancer T1G3: the choice of treatment</TI>
<SO>British Journal of Urology International</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>6</NO>
<PG>623-7</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:26:28 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:26:28 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11942979"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Botteman-2003" MODIFIED="2009-05-08 14:19:53 -0500" MODIFIED_BY="James Tacklind" NAME="Botteman 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-05-08 14:19:53 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R</AU>
<TI>The health economics of bladder cancer: a comprehensive review of the published literature</TI>
<SO>Pharmacoeconomics</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>18</NO>
<PG>1315-30</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:28:04 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:28:04 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14750899 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradner-2001" MODIFIED="2009-01-16 08:29:41 -0600" MODIFIED_BY="[Empty name]" NAME="Bradner 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-01-16 08:29:41 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradner WT</AU>
<TI>Mitomycin C: a clinical update</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2001</YR>
<VL>27</VL>
<NO>1</NO>
<PG>35-50</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:29:41 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:29:41 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11237776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brassell-2006" MODIFIED="2009-01-16 08:30:46 -0600" MODIFIED_BY="[Empty name]" NAME="Brassell 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-01-16 08:30:46 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brassell SA, Kamat AM</AU>
<TI>Contemporary intravesical treatment options for urothelial carcinoma of the bladder</TI>
<SO>Journal of the National Comprehensive Cancer Network</SO>
<YR>2006</YR>
<VL>4</VL>
<NO>10</NO>
<PG>1027-36</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:30:43 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:30:43 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17112451"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brausi-1998" MODIFIED="2009-10-06 03:02:09 -0500" MODIFIED_BY="[Empty name]" NAME="Brausi 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-10-06 03:02:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brausi M, Hurle R, Lembo A, Palladini PD</AU>
<TI>Immunotherapy with BCG in high risk recurrent bladder cancers previously treated with multiple cycles of chemotherapy: Long-term results</TI>
<SO>Acta Urologica Italica</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2</NO>
<PG>131-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brausi-2002" MODIFIED="2009-01-16 08:32:44 -0600" MODIFIED_BY="[Empty name]" NAME="Brausi 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-01-16 08:32:44 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al</AU>
<TI>Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies</TI>
<SO>European Urology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>5</NO>
<PG>523-31</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:32:44 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:32:44 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12074794 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulbul-2005" MODIFIED="2009-01-16 08:33:15 -0600" MODIFIED_BY="[Empty name]" NAME="Bulbul 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-01-16 08:33:15 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;J. Med. Liban.?&lt;/p&gt;" NOTES_MODIFIED="2009-01-16 08:33:15 -0600" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulbul MA, Husseini N, Houjaij A</AU>
<TI>Superficial bladder cancer epidemiology, diagnosis and management</TI>
<SO>The Lebanese Medical Journal</SO>
<YR>2005</YR>
<VL>53</VL>
<NO>2</NO>
<PG>107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cai-2008" MODIFIED="2009-10-06 03:12:35 -0500" MODIFIED_BY="[Empty name]" NAME="Cai 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-10-06 03:12:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, et al</AU>
<TI>Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study</TI>
<SO>The Journal of Urology</SO>
<YR>2008</YR>
<VL>180</VL>
<NO>1</NO>
<PG>110-5</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:27:58 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:27:58 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18485394"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Canda-2004" MODIFIED="2009-02-06 01:03:16 -0600" MODIFIED_BY="[Empty name]" NAME="Canda 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-06 01:03:16 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Canda AE, Tuzel E, Mungan MU, Yorukoglu K, Kirkali Z</AU>
<TI>Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder</TI>
<SO>European Urology</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>4</NO>
<PG>465-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:03:16 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:03:16 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15041110"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catanzaro-1996" MODIFIED="2009-10-06 03:13:30 -0500" MODIFIED_BY="[Empty name]" NAME="Catanzaro 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-10-06 03:13:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catanzaro F, Torelli F, Catanzaro M, Cappellano F, Pizzoccaro M, Baruffi M, et al</AU>
<TI>Conservative treatment of high-risk (T1G3) transitional carcinoma</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>1996</YR>
<VL>68</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:35:38 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:35:38 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8664915 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cervenakov-2000" MODIFIED="2009-02-06 01:03:31 -0600" MODIFIED_BY="[Empty name]" NAME="Cervenakov 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-02-06 01:03:31 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cervenakov I, Szoldova K, Mardiak J, Chovan D, Mala M, Slavov D</AU>
<TI>Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder</TI>
<SO>Bratislavské Lekárske Listy</SO>
<YR>2000</YR>
<VL>101</VL>
<NO>6</NO>
<PG>317-20</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:03:31 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:03:31 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11039202"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chung-2005" MODIFIED="2009-03-15 23:14:29 -0500" MODIFIED_BY="[Empty name]" NAME="Chung 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 23:14:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung BI</AU>
<TI>Commentary on intravesical mitoxantrone versus recombinant interferon alfa after resection of Superficial bladder cancer</TI>
<SO>American Journal of Urology Review</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cindolo-2004" MODIFIED="2009-01-16 08:39:25 -0600" MODIFIED_BY="[Empty name]" NAME="Cindolo 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-01-16 08:39:25 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cindolo L, Palmieri EA, Autorino R, Salzano L, Altieri V</AU>
<TI>Standard versus hydrophilic catheterization in the adjuvant treatment of patients with superficial bladder cancer</TI>
<SO>Urologia Internationalis</SO>
<YR>2004</YR>
<VL>73</VL>
<NO>1</NO>
<PG>19-22</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:39:25 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:39:25 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15263787"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corica-2005" MODIFIED="2009-03-20 14:01:40 -0500" MODIFIED_BY="James Tacklind" NAME="Corica 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-20 14:01:40 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corica FA, Keane TE</AU>
<TI>Bladder cancer - resection/ablation</TI>
<SO>Surgical Oncology Clinics of North America</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>2</NO>
<PG>321-52</PG>
<IDENTIFIERS MODIFIED="2009-01-16 08:40:32 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:40:32 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15817242"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalbagni-2007" MODIFIED="2009-01-16 08:41:18 -0600" MODIFIED_BY="[Empty name]" NAME="Dalbagni 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-01-16 08:41:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalbagni G</AU>
<TI>The management of superficial bladder cancer</TI>
<SO>Nature Clinical Practice. Urology</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>5</NO>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damianov-1990" MODIFIED="2009-02-06 01:03:48 -0600" MODIFIED_BY="[Empty name]" NAME="Damianov 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-02-06 01:03:48 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damianov Kh, Patrashkov T, Petkov Ts, Tonchev T, Petrov P</AU>
<TI>Nonspecific immunotherapy with BCG vaccine in bladder tumors</TI>
<SO>Khirurgiia</SO>
<YR>1990</YR>
<VL>43</VL>
<NO>1</NO>
<PG>48-53</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:03:48 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:03:48 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="2395285"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damianov-1994" MODIFIED="2009-03-20 14:02:24 -0500" MODIFIED_BY="James Tacklind" NAME="Damianov 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-03-20 14:02:24 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damianov C, Terziev T, Koleva P, Chuchkova M</AU>
<TI>Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors</TI>
<SO>Anti-Cancer Drugs</SO>
<YR>1994</YR>
<VL>53</VL>
<NO>3</NO>
<PG>298-304</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:03:59 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:03:59 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7919454"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Reijke-1996" MODIFIED="2009-01-16 08:44:47 -0600" MODIFIED_BY="[Empty name]" NAME="De Reijke 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-01-16 08:44:47 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Reijke TM, Kurth K, De Boer EC, Schamhart DHJ</AU>
<TI>Current insights in the treatment of superficial transitional cell carcinoma of the bladder</TI>
<SO>Onkologie</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>6</NO>
<PG>480-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Reijke-2005a" MODIFIED="2010-04-25 00:27:41 -0500" MODIFIED_BY="[Empty name]" NAME="De Reijke 2005a" YEAR="2005">
<REFERENCE MODIFIED="2010-04-25 00:27:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Reijke TM, Kurth KH, Sylvester RJ, Hall RR, Brausi M, van de Beek K, et al</AU>
<TI>Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer - Genito-Urinary Group Phase III Trial</TI>
<SO>The Journal of Urology</SO>
<YR>2005</YR>
<VL>173</VL>
<NO>2</NO>
<PG>405-9</PG>
<IDENTIFIERS MODIFIED="2010-04-25 00:27:41 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-16 08:45:58 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15643181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Reijke-2005b" MODIFIED="2009-05-08 14:17:23 -0500" MODIFIED_BY="James Tacklind" NAME="De Reijke 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 14:17:23 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Reijke TM, Kurth KH, Sylvester RJ</AU>
<TI>Immunotherapy in superficial bladder cancer</TI>
<SO>Enhancer - Biotherapy of Cancer</SO>
<YR>2005</YR>
<VL>3</VL>
<NO>3</NO>
<PG>17-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Denis-1987" MODIFIED="2009-03-13 20:30:40 -0500" MODIFIED_BY="[Empty name]" NAME="Denis 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-03-13 20:30:40 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Denis L, Bouffioux C, Kurth KH, Debruyne F, Sylvester R, De Pauw M</AU>
<TI>Current status of intravesical chemotherapy trials in the EORTC Urological Group. An overview</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1987</YR>
<VL>20</VL>
<NO>Suppl</NO>
<PG>S67-71</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:02:04 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:02:04 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3664947"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Stasi-2006" MODIFIED="2009-03-13 20:31:34 -0500" MODIFIED_BY="[Empty name]" NAME="Di Stasi 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-13 20:31:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, et al</AU>
<TI>Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial</TI>
<SO>The Lancet Oncology</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>1</NO>
<PG>43-51</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:01:51 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:01:51 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16389183"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Djulbegovic-2005" MODIFIED="2009-03-13 20:32:24 -0500" MODIFIED_BY="[Empty name]" NAME="Djulbegovic 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-13 20:32:24 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Djulbegovic B, Bickerdike L</AU>
<TI>High-quality evidence in oncology from 21st October to 18th November 2004: A summary</TI>
<SO>Cancer Treatment Reviews</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>3</NO>
<PG>242-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doehn-2005" MODIFIED="2009-03-01 03:29:55 -0600" MODIFIED_BY="[Empty name]" NAME="Doehn 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-01 03:29:55 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doehn C, Kausch I, Jocham D</AU>
<TI>Immunotherapy of urologic tumors</TI>
<SO>Onkologe</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>5</NO>
<PG>536-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duchek-2010" MODIFIED="2010-10-06 10:07:24 -0500" MODIFIED_BY="James Tacklind" NAME="Duchek 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-10-06 10:07:24 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duchek M, Johansson R, Jahnson S, Mestad O, Hellström P, Hellsten S, et al</AU>
<TI>Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1urinary bladder cancer. A prospective, randomized, Nordic study</TI>
<SO>European Urology</SO>
<YR>2010</YR>
<VL>57</VL>
<NO>1</NO>
<PG>25-31</PG>
<IDENTIFIERS MODIFIED="2010-04-25 08:15:39 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-25 08:15:39 -0500" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="19819617"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duque-2000" MODIFIED="2009-05-08 14:17:34 -0500" MODIFIED_BY="James Tacklind" NAME="Duque 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-05-08 14:17:34 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duque JL, Loughlin KR</AU>
<TI>An overview of the treatment of superficial bladder cancer: Intravesical chemotherapy</TI>
<SO>The Urologic Clinics of North America</SO>
<YR>2000</YR>
<VL>27</VL>
<NO>1</NO>
<PG>125-35</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:11:10 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:11:10 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10696251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El_x002d_Sebaie-2005" MODIFIED="2009-03-13 20:33:58 -0500" MODIFIED_BY="[Empty name]" NAME="El-Sebaie 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-13 20:33:58 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El-Sebaie M, Zaghloul MS, Howard G, Mokhtar A</AU>
<TI>Squamous cell carcinoma of the bilharzial and non-bilharzial urinary bladder: A review of etiological features, natural history, and management</TI>
<SO>International Journal of Clinical Oncology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:13:23 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:13:23 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 15729596 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Erol-1994" MODIFIED="2009-03-13 20:35:30 -0500" MODIFIED_BY="[Empty name]" NAME="Erol 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-03-13 20:35:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Erol A, Ozqür S, Basar M, Cetin S</AU>
<TI>Trial with bacillus Calmette-Guerin and epirubicin combination in the prophylaxis of superficial bladder cancer</TI>
<SO>Urologia Internationalis</SO>
<YR>1994</YR>
<VL>52</VL>
<NO>2</NO>
<PG>69-72</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:16:55 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:16:55 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8178379"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fradet-1995" MODIFIED="2009-03-13 20:36:11 -0500" MODIFIED_BY="[Empty name]" NAME="Fradet 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-03-13 20:36:11 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fradet Y</AU>
<TI>Treatment of superficial bladder cancer</TI>
<SO>Current Opinion in Urology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>5</NO>
<PG>267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gasion-2006" MODIFIED="2009-03-13 20:36:38 -0500" MODIFIED_BY="[Empty name]" NAME="Gasion 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-13 20:36:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gasión JPB, Cruz JFJ</AU>
<TI>Improving efficacy of intravesical chemotherapy</TI>
<SO>European Urology</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>2</NO>
<PG>225-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-2002" MODIFIED="2009-03-13 20:37:29 -0500" MODIFIED_BY="[Empty name]" NAME="Goldberg 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-13 20:37:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg EP, Hadba AR, Almond BA, Marotta JS</AU>
<TI>Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery</TI>
<SO>The Journal of Pharmacy and Pharmacology</SO>
<YR>2002</YR>
<VL>54</VL>
<NO>2</NO>
<PG>159-80</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:25:20 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:25:20 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11848280"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gontero-2006" MODIFIED="2009-05-08 14:20:44 -0500" MODIFIED_BY="James Tacklind" NAME="Gontero 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-05-08 14:20:44 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gontero P, Frea B</AU>
<TI>Actual experience and future development of gemcitabine in superficial bladder cancer</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>Suppl 5</NO>
<PG>v123-8</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:27:09 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:27:09 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16807439"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grasso-2001" MODIFIED="2009-03-13 20:39:20 -0500" MODIFIED_BY="[Empty name]" NAME="Grasso 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-13 20:39:20 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grasso M, Torelli F, Scannapieco G, Franzoso F, Lania C</AU>
<TI>Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2</TI>
<SO>Journal of Immunotherapy</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>2</NO>
<PG>184-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gschwend-2006" MODIFIED="2009-11-30 09:13:53 -0600" MODIFIED_BY="James Tacklind" NAME="Gschwend 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-30 09:13:53 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gschwend J</AU>
<TI>Bladder carcer - What's new</TI>
<SO>Der Urologe - Ausgabe A</SO>
<YR>2006</YR>
<VL>45</VL>
<NO>4</NO>
<PG>496-8</PG>
<IDENTIFIERS MODIFIED="2009-10-06 03:27:28 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-10-06 03:27:28 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16568255"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gwynn-2005" MODIFIED="2009-03-13 20:53:22 -0500" MODIFIED_BY="[Empty name]" NAME="Gwynn 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-13 20:53:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gwynn ES, Clark PE, Hall MC</AU>
<TI>Recent advances in the treatment of bladder cancer</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2005</YR>
<VL>5</VL>
<NO>6</NO>
<PG>1023-30</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:35:23 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:35:23 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16336093 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gwynn-2006" MODIFIED="2009-11-30 09:14:10 -0600" MODIFIED_BY="James Tacklind" NAME="Gwynn 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-11-30 09:14:10 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gwynn ES, Clark PE</AU>
<TI>Bladder cancer</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>277-83</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:41:08 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:41:08 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16552241"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hall-1994" MODIFIED="2009-03-20 13:58:08 -0500" MODIFIED_BY="James Tacklind" NAME="Hall 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-03-20 13:58:08 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hall RR</AU>
<TI>Superficial bladder cancer</TI>
<SO>British Medical Journal (Clinical research ed.)</SO>
<YR>1994</YR>
<VL>308</VL>
<NO>6933</NO>
<PG>910-3</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:56:12 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:56:12 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8173377"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinotsu-1999" MODIFIED="2009-02-06 01:57:18 -0600" MODIFIED_BY="[Empty name]" NAME="Hinotsu 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-02-06 01:57:18 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinotsu S, Akaza H, Ohashi Y, Kotake T</AU>
<TI>Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: A combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function</TI>
<SO>Cancer</SO>
<YR>1999</YR>
<VL>86</VL>
<NO>9</NO>
<PG>1818-26</PG>
<IDENTIFIERS MODIFIED="2009-02-06 01:57:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 01:57:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10547556"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hong-2005" MODIFIED="2009-03-13 20:58:19 -0500" MODIFIED_BY="[Empty name]" NAME="Hong 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-13 20:58:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hong SJ, Choi HY, Ahn HJ, Kim CS, Yang WJ</AU>
<TI>Effect of intravesical high dose epirubicin versus Bacillus Calmette-Guérin instillation on the recurrence and progression of superficial bladder cancer: A prospective, multicenter study</TI>
<SO>The Korean Journal of Urology</SO>
<YR>2005</YR>
<VL>46</VL>
<NO>7</NO>
<PG>677-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huncharek-2001" MODIFIED="2009-03-13 20:58:55 -0500" MODIFIED_BY="[Empty name]" NAME="Huncharek 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-13 20:58:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huncharek M, McGarry R, Kupelnick B</AU>
<TI>Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis</TI>
<SO>Anticancer Research</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1B</NO>
<PG>765-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:02:16 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:02:16 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11299841"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huncharek-2003" MODIFIED="2009-03-13 20:59:34 -0500" MODIFIED_BY="[Empty name]" NAME="Huncharek 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-13 20:59:34 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huncharek M, Kupelnick B</AU>
<TI>Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Metaanalytic reevaluation</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2003</YR>
<VL>26</VL>
<NO>4</NO>
<PG>402-7</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:03:40 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:03:40 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12902895"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huncharek-2004" MODIFIED="2009-08-26 09:16:17 -0500" MODIFIED_BY="[Empty name]" NAME="Huncharek 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-13 21:00:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huncharek M, Kupelnick B</AU>
<TI>The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: A meta analytic comparison of chemotherapy versus bacilli Calmette-Guérin immunotherapy</TI>
<SO>American Journal of Clinical Oncology</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>5</NO>
<PG>522-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-26 09:16:17 -0500" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Iida-2009" MODIFIED="2009-11-30 09:15:14 -0600" MODIFIED_BY="James Tacklind" NAME="Iida 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-11-30 09:15:14 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Iida S, Kondo T, Kobayashi H, Hashimoto Y, Goya N, Tanabe K</AU>
<TI>Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience</TI>
<SO>International Journal of Urology</SO>
<YR>2009</YR>
<VL>16</VL>
<NO>3</NO>
<PG>287-92</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:19:03 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:19:03 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19207115"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Josephson-2007" MODIFIED="2009-03-13 21:01:22 -0500" MODIFIED_BY="[Empty name]" NAME="Josephson 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-13 21:01:22 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Josephson D, Pasin E, Stein JP</AU>
<TI>Superficial bladder cancer: part 2. Management</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>4</NO>
<PG>567-81</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:09:17 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:09:17 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17428176"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kausch-2006" MODIFIED="2009-03-13 21:01:33 -0500" MODIFIED_BY="[Empty name]" NAME="Kausch 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-13 21:01:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kausch I, Doehn C, Jocham D</AU>
<TI>Recent improvements in the detection and treatment of nonmuscle-invasive bladder cancer</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>9</NO>
<PG>1301-11</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:10:44 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:10:44 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17020462"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kondo-1999" MODIFIED="2009-03-13 21:02:37 -0500" MODIFIED_BY="[Empty name]" NAME="Kondo 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-03-13 21:02:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kondo T, Onitsuka S, Ryoji O, Kihara T, Goto Y, Satoh T, et al</AU>
<TI>Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy</TI>
<SO>International Journal of Urology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>4</NO>
<PG>178-3</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:12:28 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:12:28 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10226834"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konukoglu-1995" MODIFIED="2009-03-13 21:03:29 -0500" MODIFIED_BY="[Empty name]" NAME="Konukoglu 1995" YEAR="1995">
<REFERENCE MODIFIED="2009-03-13 21:03:29 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konuko&#287;lu D, Akcay T, Erözenci A</AU>
<TI>The importance urinary glycosaminoglycan as a marker for superficial bladder tumors</TI>
<SO>Cancer Biochemistry Biophysics</SO>
<YR>1995</YR>
<VL>15</VL>
<NO>2</NO>
<PG>91-4</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:15:46 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:15:46 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8590440"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konukoglu-1996" MODIFIED="2009-03-13 21:04:32 -0500" MODIFIED_BY="[Empty name]" NAME="Konukoglu 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-13 21:04:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konuko&#287;lu D, Akcay T, Celik C, Erözenci A</AU>
<TI>Urinary zinc levels in patients with superficial bladder cancer</TI>
<SO>Journal of Basic and Clinical Physiology and Pharmacology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>2</NO>
<PG>115-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:17:04 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:17:04 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8876430"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koya-2006" MODIFIED="2009-03-13 21:05:06 -0500" MODIFIED_BY="[Empty name]" NAME="Koya 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-13 21:05:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koya MP, Simon MA, Soloway MS</AU>
<TI>Complications of intravesical therapy for urothelial cancer of the bladder</TI>
<SO>The Journal of Urology</SO>
<YR>2006</YR>
<VL>175</VL>
<NO>6</NO>
<PG>2004-10</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:18:44 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:18:44 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16697786"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumar-2002" MODIFIED="2009-03-13 21:09:33 -0500" MODIFIED_BY="[Empty name]" NAME="Kumar 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-13 21:09:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kumar V, Lawson AH</AU>
<TI>Carcinoma-in-situ bladder - An early indication for cystectomy?</TI>
<SO>Indian Journal of Urology</SO>
<YR>2002</YR>
<VL>18</VL>
<NO>2</NO>
<PG>136-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurth-2000" MODIFIED="2009-03-13 21:10:31 -0500" MODIFIED_BY="[Empty name]" NAME="Kurth 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-13 21:10:31 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurth KH, Bouffioux C, Sylvester R, Van der Meijden APM, Oosterlinck W, Brausi M</AU>
<TI>Treatment of superficial bladder tumors: Achievements and needs</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>Suppl 3</NO>
<PG>1-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:21:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:21:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10828681"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamm-1996" MODIFIED="2009-03-13 21:12:13 -0500" MODIFIED_BY="[Empty name]" NAME="Lamm 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-13 21:12:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamm DL, Torti FM</AU>
<TI>Bladder cancer</TI>
<SO>CA: a Cancer Journal for Clinicians</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>2</NO>
<PG>93-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamm-1999" MODIFIED="2009-03-13 21:13:07 -0500" MODIFIED_BY="[Empty name]" NAME="Lamm 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-03-13 21:13:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamm D, Herr H, Jakse G, Kuroda M, Mostofi FK, Okajima E, et al</AU>
<TI>Updated concepts and treatment of carcinoma in situ</TI>
<SO>Urologic Oncology</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>4-5</NO>
<PG>130-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamm-2004" MODIFIED="2009-03-13 21:13:37 -0500" MODIFIED_BY="[Empty name]" NAME="Lamm 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-13 21:13:37 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamm DL</AU>
<TI>Management of bladder cancer</TI>
<SO>The Journal of Urology</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>6I</NO>
<PG>2482-3</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:29:17 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:29:17 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15126880"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lamm-2005" MODIFIED="2009-05-08 14:09:22 -0500" MODIFIED_BY="James Tacklind" NAME="Lamm 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 14:09:22 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lamm DL, McGee WR, Hale K</AU>
<TI>Bladder cancer: current optimal intravesical treatment</TI>
<SO>Urologic Nursing</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>5</NO>
<PG>323-6, 331-2</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:30:15 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:30:15 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16294610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lerner-2005" MODIFIED="2009-05-08 14:09:06 -0500" MODIFIED_BY="James Tacklind" NAME="Lerner 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-05-08 14:09:06 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lerner S.P</AU>
<TI>Bladder cancer clinical trials</TI>
<SO>Urologic Oncology: Seminars and Original Investigations</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>4</NO>
<PG>275-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lockyer-2001" MODIFIED="2009-03-15 21:32:41 -0500" MODIFIED_BY="[Empty name]" NAME="Lockyer 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-15 21:32:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lockyer CRW, Gillatt DA</AU>
<TI>BCG immunotherapy for superficial bladder cancer</TI>
<SO>Journal of the Royal Society of Medicine</SO>
<YR>2001</YR>
<VL>94</VL>
<NO>3</NO>
<PG>119-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lodde-2004" MODIFIED="2009-02-06 02:33:30 -0600" MODIFIED_BY="[Empty name]" NAME="Lodde 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-06 02:33:30 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lodde M, Mian C, Negri G, Vittadello F, Comploj E, Palermo S, et al</AU>
<TI>Effect of intravesical instillation on performance of uCYT+ test</TI>
<SO>Urology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>5</NO>
<PG>878-81</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:33:30 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:33:30 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15134970"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lorusso-2005" MODIFIED="2010-10-06 10:11:15 -0500" MODIFIED_BY="James Tacklind" NAME="Lorusso 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-06 10:11:15 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lorusso V, Silvestris N</AU>
<TI>Systemic chemotherapy for patients with advanced and metastatic bladder cancer: Current status and future directions</TI>
<SO>Annals of Oncology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>Suppl</NO>
<PG>iv85-9</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:35:13 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:35:13 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15923437"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstr_x00f6_m-2000" MODIFIED="2009-03-15 21:41:18 -0500" MODIFIED_BY="[Empty name]" NAME="Malmström 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-15 21:41:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Malmström P</AU>
<TI>Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>Suppl 1</NO>
<PG>16-20</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:35:34 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:35:34 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10575267"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstr_x00f6_m-2003" MODIFIED="2009-03-15 21:42:52 -0500" MODIFIED_BY="[Empty name]" NAME="Malmström 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-15 21:42:52 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmström PU</AU>
<TI>Intravesical therapy of superficial bladder cancer</TI>
<SO>Critical Reviews in Oncology/Hematology</SO>
<YR>2003</YR>
<VL>47</VL>
<NO>2</NO>
<PG>109-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malmstr_x00f6_m-2004" MODIFIED="2009-03-15 21:43:50 -0500" MODIFIED_BY="[Empty name]" NAME="Malmström 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-15 21:43:50 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malmström PU</AU>
<TI>Advances in intravesical therapy of urinary bladder cancer</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>6</NO>
<PG>1057-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinez-2001" MODIFIED="2009-03-15 21:45:09 -0500" MODIFIED_BY="[Empty name]" NAME="Martinez 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-15 21:45:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinez Portillo FJ, Alken P</AU>
<TI>Current problems and needs in the treatment of pT1 G3 bladder carcinoma</TI>
<SO>International Urology and Nephrology</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>1</NO>
<PG>29-40</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:43:32 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:43:32 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12090335 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McFarlane-1996" MODIFIED="2009-03-15 21:46:07 -0500" MODIFIED_BY="[Empty name]" NAME="McFarlane 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-15 21:46:07 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McFarlane JP, Ellis BW, Harland SJ</AU>
<TI>The management of superficial bladder cancer: An interactive seminar</TI>
<SO>British Journal of Urology</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>3</NO>
<PG>372-8</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:45:19 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:45:19 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 8881945 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mehraban-2005" MODIFIED="2009-03-15 21:46:47 -0500" MODIFIED_BY="[Empty name]" NAME="Mehraban 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 21:46:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mehraban D, Esfahani F</AU>
<TI>Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906)</TI>
<SO>The Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>3</NO>
<PG>1151</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:46:46 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:46:46 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16094088"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Melekos-2000" MODIFIED="2009-03-15 21:47:23 -0500" MODIFIED_BY="[Empty name]" NAME="Melekos 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-15 21:47:23 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Melekos MD, Moutzouris GD</AU>
<TI>Intravesical therapy of superficial bladder cancer</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2000</YR>
<VL>6</VL>
<NO>3</NO>
<PG>345-59</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:46:59 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 02:46:59 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10637383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merkle-1990" MODIFIED="2009-03-15 21:48:09 -0500" MODIFIED_BY="[Empty name]" NAME="Merkle 1990" YEAR="1990">
<REFERENCE MODIFIED="2009-03-15 21:48:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merkle W, Burk K</AU>
<TI>Preliminary results of a randomized phase-II-study BCG vs epirubicin as intravesical prophylaxis of urothelial bladder tumors</TI>
<SO>Journal of Cancer Research and Clinical Oncology</SO>
<YR>1990</YR>
<VL>116</VL>
<NO>Suppl</NO>
<PG>545</PG>
<IDENTIFIERS MODIFIED="2009-02-06 02:53:43 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitropoulos-2005" MODIFIED="2009-03-15 21:57:13 -0500" MODIFIED_BY="[Empty name]" NAME="Mitropoulos 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 21:57:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitropoulos DN</AU>
<TI>Novel insights into the mechanism of action of intravesical immunomodulators</TI>
<SO>In Vivo (Athens, Greece)</SO>
<YR>2005</YR>
<VL>19</VL>
<NO>3</NO>
<PG>611-21</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:03:19 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:03:19 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15875784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morganstern-1998" MODIFIED="2009-03-15 21:49:33 -0500" MODIFIED_BY="[Empty name]" NAME="Morganstern 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-03-15 21:49:33 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morganstern D, Garnick MB</AU>
<TI>Genitourinary cancers in older adults</TI>
<SO>Clinics in Geriatric Medicine</SO>
<YR>1998</YR>
<VL>14</VL>
<NO>2</NO>
<PG>333-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munro-2006" MODIFIED="2009-03-15 21:51:17 -0500" MODIFIED_BY="[Empty name]" NAME="Munro 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-15 21:51:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munro N, Whelan P</AU>
<TI>Bladder cancer</TI>
<SO>Surgery (Oxford)</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>5</NO>
<PG>181-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newling-2001" MODIFIED="2009-03-15 21:50:32 -0500" MODIFIED_BY="[Empty name]" NAME="Newling 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-03-15 21:50:32 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newling DW, Hetherington J, Sundaram SK, Robinson MR, Kisbenedek L</AU>
<TI>The use of valrubicin for the chemoresection of superficial bladder cancer - A marker lesion study</TI>
<SO>European Urology</SO>
<YR>2001</YR>
<VL>39</VL>
<NO>6</NO>
<PG>643-7</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:07:59 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:07:59 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11464052 "/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-2001" MODIFIED="2010-10-06 10:14:25 -0500" MODIFIED_BY="James Tacklind" NAME="Nilsson 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-06 10:14:25 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson S, Ragnhammar P, Glimelius B, Nygren P</AU>
<TI>A systematic overview of chemotherapy effects in urothelial bladder cancer</TI>
<SO>Acta Oncologica (Stockholm, Sweden)</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>2-3</NO>
<PG>371-90</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:09:14 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:09:14 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11441942"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Donnell-2003" MODIFIED="2009-03-15 21:58:35 -0500" MODIFIED_BY="[Empty name]" NAME="O'Donnell 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-15 21:58:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Donnell MA</AU>
<TI>Combined bacillus Calmette-Guerin and interferon use in superficial bladder cancer</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>6</NO>
<PG>809-21</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:11:06 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:11:06 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14686703"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ojea-Calvo-1994" MODIFIED="2009-06-26 09:24:22 -0500" MODIFIED_BY="James Tacklind" NAME="Ojea Calvo 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-06-26 09:24:22 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ojea Calvo A, Nogueira March JL, Alonso A, Verez M, Rodriguez Iglesias B, Benavente J, et al</AU>
<TI>Toxicity of prophylaxis of superficial bladder tumors</TI>
<SO>Actas Urologicas Espa&#328;olas</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>7</NO>
<PG>714-22</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:12:05 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:12:05 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7942230"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okeke-2005" MODIFIED="2009-03-15 22:01:13 -0500" MODIFIED_BY="[Empty name]" NAME="Okeke 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 22:01:13 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okeke AA, Probert JL, Gillatt DA, Schwaibold H</AU>
<TI>Is intravesical chemotherapy for superficial bladder cancer still justified?</TI>
<SO>BJU International</SO>
<YR>2005</YR>
<VL>96</VL>
<NO>6</NO>
<PG>763-7</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:13:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:13:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16153195"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Onrust-1999" MODIFIED="2009-03-15 22:02:09 -0500" MODIFIED_BY="[Empty name]" NAME="Onrust 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-03-15 22:02:09 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Onrust SV, Wiseman LR, Goa KL</AU>
<TI>Epirubicin: a review of its intravesical use in superficial bladder cancer</TI>
<SO>Drugs &amp; Aging</SO>
<YR>1999</YR>
<VL>15</VL>
<NO>4</NO>
<PG>307-33</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:14:11 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:14:11 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10582777"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-2001a" MODIFIED="2009-03-15 22:02:41 -0500" MODIFIED_BY="[Empty name]" NAME="Oosterlinck 2001a" YEAR="2001">
<REFERENCE MODIFIED="2009-03-15 22:02:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W, Bono AV, Mack D, Hall R, Sylvester R, de Balincourt C, et al</AU>
<TI>Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions</TI>
<SO>European Urology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>5</NO>
<PG>515-7</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:14:24 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:14:24 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11752858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-2001b" MODIFIED="2009-03-15 22:02:27 -0500" MODIFIED_BY="[Empty name]" NAME="Oosterlinck 2001b" YEAR="2001">
<REFERENCE MODIFIED="2009-03-15 22:02:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W</AU>
<TI>The management of superficial bladder cancer</TI>
<SO>BJU International</SO>
<YR>2001</YR>
<VL>87</VL>
<NO>2</NO>
<PG>135-40</PG>
<IDENTIFIERS MODIFIED="2009-02-06 03:16:24 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-06 03:16:24 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11167630"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-2004" MODIFIED="2009-03-15 22:03:44 -0500" MODIFIED_BY="[Empty name]" NAME="Oosterlinck 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-15 22:03:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W</AU>
<TI>Guidelines on diagnosis and treatment of superficial bladder cancer</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>1</NO>
<PG>65-72</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:23:43 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:23:43 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15195031"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oosterlinck-2005" MODIFIED="2009-02-08 01:27:00 -0600" MODIFIED_BY="[Empty name]" NAME="Oosterlinck 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-02-08 01:27:00 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell PJ, Malmström PU, et al</AU>
<TI>Low-grade Ta (noninvasive) urothelial carcinoma of the bladder</TI>
<SO>Urology</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>6 suppl 1</NO>
<PG>75-89</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:27:00 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:27:00 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16399417"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozen-1994" MODIFIED="2009-03-15 22:04:18 -0500" MODIFIED_BY="[Empty name]" NAME="Ozen 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-03-15 22:04:18 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozen H</AU>
<TI>Transitional cell carcinoma of the bladder</TI>
<SO>Current Opinion in Oncology</SO>
<YR>1994</YR>
<VL>6</VL>
<NO>3</NO>
<PG>313-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:29:47 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:29:47 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8080861"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pagliaro-2006" MODIFIED="2009-03-15 22:05:03 -0500" MODIFIED_BY="[Empty name]" NAME="Pagliaro 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-15 22:05:03 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pagliaro LC, Sharma P</AU>
<TI>Review of metastatic bladder cancer</TI>
<SO>Minerva Urologica e Nefrologica</SO>
<YR>2006</YR>
<VL>58</VL>
<NO>1</NO>
<PG>53-71</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:32:16 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:32:16 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16760884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Patard-2003" MODIFIED="2009-03-15 22:05:27 -0500" MODIFIED_BY="[Empty name]" NAME="Patard 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-15 22:05:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Patard JJ, Rodriguez A, Lobel B</AU>
<TI>The current status of intravesical therapy for superficial bladder cancer</TI>
<SO>Current Opinion in Oncology</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>5</NO>
<PG>357-62</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:33:26 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:33:26 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12917511"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pavone_x002d_Macaluso-1993" MODIFIED="2009-06-26 09:24:48 -0500" MODIFIED_BY="James Tacklind" NAME="Pavone-Macaluso 1993" YEAR="1993">
<REFERENCE MODIFIED="2009-06-26 09:24:48 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pavone-Macaluso M, Tripi M, Ingargiola GB, Corselli G, Pavone C, Serretta V</AU>
<TI>Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin</TI>
<SO>Journal of Chemotherapy</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>3</NO>
<PG>207-11</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:34:19 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:34:19 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8371131"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pegoraro-1996" MODIFIED="2009-11-30 09:07:35 -0600" MODIFIED_BY="James Tacklind" NAME="Pegoraro 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-11-30 09:07:35 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pegoraro C, Bondovalli C, Dall'Oglio B, Schiavon L, Luciano M, Parma A</AU>
<TI>T1G3 bladder tumors: 5 years later</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>1996</YR>
<VL>68</VL>
<NO>1</NO>
<PG>35-8</PG>
<IDENTIFIERS MODIFIED="2009-03-16 09:41:08 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-16 09:41:08 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8664919"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perabo-2004" MODIFIED="2009-02-08 01:37:11 -0600" MODIFIED_BY="[Empty name]" NAME="Perabo 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-02-08 01:37:11 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perabo FG, Müller SC</AU>
<TI>Current and new strategies in immunotherapy for superficial bladder cancer</TI>
<SO>Urology</SO>
<YR>2004</YR>
<VL>64</VL>
<NO>3</NO>
<PG>409-21</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:37:11 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:37:11 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15351555"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pham-1997" MODIFIED="2009-03-15 22:09:15 -0500" MODIFIED_BY="[Empty name]" NAME="Pham 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-03-15 22:09:15 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pham HT, Soloway MS</AU>
<TI>High-risk superficial bladder cancer: Intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder</TI>
<SO>Seminars in Urologic Oncology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>3</NO>
<PG>147-53</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:38:21 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:38:21 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9394909"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Racioppi-2007" MODIFIED="2009-10-05 10:50:48 -0500" MODIFIED_BY="James Tacklind" NAME="Racioppi 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-10-05 10:50:48 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Racioppi M, Volpe A, Falabella R, Pinto F, Sacco E, Gulino G, et al</AU>
<TI>The cost of treatment and follow-up of bladder cancer in Italy</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>2007</YR>
<VL>79</VL>
<NO>3</NO>
<PG>111-7</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:34:35 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:34:35 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="18041361"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Raitanen-2001" MODIFIED="2009-11-30 09:08:05 -0600" MODIFIED_BY="James Tacklind" NAME="Raitanen 2001" YEAR="2001">
<REFERENCE MODIFIED="2009-11-30 09:08:05 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Raitanen MP, Hellström P, Marttila T, Korhonen H, Talja M, Ervasti J, et al</AU>
<TI>Effect of intravesical instillations on the human complement factor H related protein (BTA stat) test</TI>
<SO>European Urology</SO>
<YR>2001</YR>
<VL>40</VL>
<NO>4</NO>
<PG>422-6</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:41:23 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:41:23 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11713397"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roggia-1996" MODIFIED="2009-03-15 22:09:59 -0500" MODIFIED_BY="[Empty name]" NAME="Roggia 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-15 22:09:59 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roggia A, Pozzi E, Malvestiti GM</AU>
<TI>Transitional carcinoma of the bladder at the T1G3 stage: personal experience</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>1996</YR>
<VL>68</VL>
<NO>1</NO>
<PG>25-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:41:47 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:41:47 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8664916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romics-1996" MODIFIED="2009-03-15 22:18:38 -0500" MODIFIED_BY="[Empty name]" NAME="Romics 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-15 22:18:38 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romics I, Foldes J, Kalman J, Polyak L, Sarkady T, Toth C, et al</AU>
<TI>Results of local treatment of superficial bladder cancer patients with BCG versus interferon versus interferon + epirubicin. Multicentric, randomized, prospective study (preliminary report)</TI>
<SO>Magyar Urologia</SO>
<YR>1996</YR>
<VL>8</VL>
<NO>4</NO>
<PG>317-21</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:44:20 -0600" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santhanam-2002" MODIFIED="2009-03-20 14:07:21 -0500" MODIFIED_BY="James Tacklind" NAME="Santhanam 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-03-20 14:07:21 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santhanam S, Decatris M, O'Byrne K</AU>
<TI>Potential of interferon-&#945; in solid tumours: Part 2</TI>
<SO>BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy</SO>
<YR>2002</YR>
<VL>16</VL>
<NO>5</NO>
<PG>349-72</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:48:33 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:48:33 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12408739"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scher-1994" MODIFIED="2009-03-15 22:20:05 -0500" MODIFIED_BY="[Empty name]" NAME="Scher 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-03-15 22:20:05 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scher HI</AU>
<TI>Principles of oncology and immunology, and tumors of bladder, penis and urethra</TI>
<SO>The Journal of Urology</SO>
<YR>1994</YR>
<VL>152</VL>
<NO>2</NO>
<PG>568-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Serretta-1996" MODIFIED="2009-03-07 02:22:19 -0600" MODIFIED_BY="[Empty name]" NAME="Serretta 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-07 02:22:19 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Serretta V, Piazza S, Pavone C, Piazza B, Pavone-Macaluso M</AU>
<TI>Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder</TI>
<SO>Urology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>5</NO>
<PG>647-51</PG>
<IDENTIFIERS MODIFIED="2009-03-07 02:22:19 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-07 02:22:19 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8650860"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shelley-2003" MODIFIED="2010-07-03 09:14:07 -0500" MODIFIED_BY="[Empty name]" NAME="Shelley 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-11-30 09:09:00 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="COCHRANE_REVIEW">
<AU>Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M</AU>
<TI>Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-03-07 02:54:41 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-07 02:54:41 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003231"/>
<IDENTIFIER MODIFIED="2009-02-08 01:56:01 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE=" 12917955"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shelley-2010" MODIFIED="2010-07-03 09:14:58 -0500" MODIFIED_BY="[Empty name]" NAME="Shelley 2010" YEAR="2010">
<REFERENCE MODIFIED="2010-04-25 08:06:53 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shelley MD, Mason MD, Kynaston H</AU>
<TI>Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses</TI>
<SO>Cancer treatment reviews</SO>
<YR>2010</YR>
<VL>36</VL>
<NO>3</NO>
<PG>195-205</PG>
<IDENTIFIERS MODIFIED="2010-04-25 08:06:53 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-04-25 08:06:53 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="20079574"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skinner-2007" MODIFIED="2009-03-15 22:21:06 -0500" MODIFIED_BY="[Empty name]" NAME="Skinner 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-15 22:21:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Skinner E</AU>
<TI>Will a new intravesical chemotherapy agent improve the treatment of non-muscle-invasive bladder cancer?</TI>
<SO>Nature Clinical Practice. Urology</SO>
<YR>2007</YR>
<VL>4</VL>
<NO>5</NO>
<PG>248-9</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:57:50 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:57:50 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17389884"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloway-1992" MODIFIED="2009-03-15 22:22:02 -0500" MODIFIED_BY="[Empty name]" NAME="Soloway 1992" YEAR="1992">
<REFERENCE MODIFIED="2009-03-15 22:22:02 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloway MS, Perito PE</AU>
<TI>Superficial bladder cancer: diagnosis, surveillance and treatment</TI>
<SO>Journal of Cellular Biochemistry. Supplement</SO>
<YR>1992</YR>
<VL>161</VL>
<PG>120-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 01:58:38 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 01:58:38 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1305674"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soloway-2005" MODIFIED="2009-11-30 09:04:49 -0600" MODIFIED_BY="James Tacklind" NAME="Soloway 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-11-30 09:04:49 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soloway MS</AU>
<TI>Editorial comment</TI>
<SO>International Brazilian Journal of Urology</SO>
<YR>2005</YR>
<VL>31</VL>
<NO>3</NO>
<PG>212-3</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:01:45 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:01:45 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16052741"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stankovi_x0107_-2007" MODIFIED="2009-08-26 09:38:47 -0500" MODIFIED_BY="[Empty name]" NAME="Stankovi&#263; 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-26 09:38:47 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stankovi&#263; J, Dini&#263; L, Pavlovi&#263; S</AU>
<TI>Superficial urinary bladder tumors treatment results--a 10-year experience</TI>
<SO>Vojnosanit Pregl</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>9</NO>
<PG>629-34</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:38:47 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:38:47 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17969819"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sylvester-2003" MODIFIED="2010-05-08 11:33:14 -0500" MODIFIED_BY="[Empty name]" NAME="Sylvester 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-15 22:23:45 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sylvester RJ, van der Meijden AP, Oosterlinck W, Hoeltl W, Bono AV</AU>
<TI>The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial</TI>
<SO>European Urology</SO>
<YR>2003</YR>
<VL>44</VL>
<NO>4</NO>
<PG>423-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:04:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:04:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14499675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sylvester-2005a" MODIFIED="2010-05-08 11:33:27 -0500" MODIFIED_BY="[Empty name]" NAME="Sylvester 2005a" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 22:24:01 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K</AU>
<TI>Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials</TI>
<SO>The Journal of Urology</SO>
<YR>2005</YR>
<VL>174</VL>
<NO>1</NO>
<PG>86-91</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:04:49 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:04:49 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15947584"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sylvester-2005b" MODIFIED="2010-05-08 11:33:33 -0500" MODIFIED_BY="[Empty name]" NAME="Sylvester 2005b" YEAR="2005">
<REFERENCE MODIFIED="2009-02-08 02:06:50 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sylvester RJ, van der Meijden A, Witjes JA, Jakse G, Nonomura N, Cheng C, et al</AU>
<TI>High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder</TI>
<SO>Urology</SO>
<YR>2005</YR>
<VL>66</VL>
<NO>6 Suppl 1</NO>
<PG>90-107</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:06:50 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:06:50 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16399418"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sylvester-2009" MODIFIED="2010-05-08 11:33:39 -0500" MODIFIED_BY="[Empty name]" NAME="Sylvester 2009" YEAR="2009">
<REFERENCE MODIFIED="2009-10-06 03:39:35 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sylvester RJ, Oosterlinck W, O'Donnell M</AU>
<TI>Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study</TI>
<SO>The Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>1</NO>
<PG>410</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:23:54 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:23:54 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="19010500"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takahashi-1996" MODIFIED="2009-03-15 22:24:57 -0500" MODIFIED_BY="[Empty name]" NAME="Takahashi 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-15 22:24:57 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takahashi N, Nishimura S, Kawaguchi T</AU>
<TI>Intra-arterial chemotherapy for muscle-invasive urinary bladder cancer</TI>
<SO>Hinyokika Kiyo. Acta Urologica Japonica</SO>
<YR>1996</YR>
<VL>42</VL>
<NO>4</NO>
<PG>263-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:08:34 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:08:34 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8693957"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Takashi-2000" MODIFIED="2009-03-15 22:25:19 -0500" MODIFIED_BY="[Empty name]" NAME="Takashi 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-15 22:25:19 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Takashi M, Schenck U, Koshikawa T, Nakashima N, Ohshima S</AU>
<TI>Cytological changes induced by intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer</TI>
<SO>Urologia Internationalis</SO>
<YR>2000</YR>
<VL>64</VL>
<NO>2</NO>
<PG>74-81</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:10:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:10:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10810268"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trinchieri-2005" MODIFIED="2009-03-15 22:26:44 -0500" MODIFIED_BY="[Empty name]" NAME="Trinchieri 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 22:26:44 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trinchieri A, Bonacina P, Butti A, Cappoli S, Esposito N, Invernizzi S, et al</AU>
<TI>Conservative treatment of high grade superficial bladder tumours</TI>
<SO>Archivio Italiano di Urologia, Andrologia</SO>
<YR>2005</YR>
<VL>77</VL>
<NO>4</NO>
<PG>215-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:11:08 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:11:08 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16444936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsujikawa-2003" MODIFIED="2009-03-15 22:28:55 -0500" MODIFIED_BY="[Empty name]" NAME="Tsujikawa 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-03-15 22:28:55 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsujikawa K, Yamamoto N, Fujita K, Sugao H</AU>
<TI>Prophylactic intravesical instillation therapy with mitomycin-C and adriamycin for recurrent superficial bladder cancer</TI>
<SO>Nishinihon Journal of Urology</SO>
<YR>2003</YR>
<VL>65</VL>
<NO>2</NO>
<PG>51-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uekado-1994" MODIFIED="2010-10-06 10:19:26 -0500" MODIFIED_BY="James Tacklind" NAME="Uekado 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-10-06 10:19:26 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uekado Y, Hirano A, Shinka T, Ohkawa T</AU>
<TI>The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>Suppl</NO>
<PG>S65-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:14:58 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:14:58 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7994790"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijden-2003a" MODIFIED="2010-06-25 09:44:17 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijden 2003a" YEAR="2003">
<REFERENCE MODIFIED="2010-06-25 09:44:17 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijden AG, Witjes JA</AU>
<TI>Intravesical chemotherapy: An update - New trends and perspectives</TI>
<SO>EAU Update Series</SO>
<YR>2003</YR>
<VL>1</VL>
<NO>2</NO>
<PG>71-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijden-2003b" MODIFIED="2010-06-25 09:44:01 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijden 2003b" YEAR="2003">
<REFERENCE MODIFIED="2010-06-25 09:44:01 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijden AG, Witjes JA</AU>
<TI>New treatments for superficial bladder cancer</TI>
<SO>Nederlands Tijdschrift voor Urologie</SO>
<YR>2003</YR>
<VL>11</VL>
<NO>3</NO>
<PG>67-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Heijden-2006" MODIFIED="2009-03-15 22:33:41 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijden 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-03-15 22:33:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijden AG, Moonen PM, Cornel EB, Vergunst H, de Reijke TM, van Boven E, et al</AU>
<TI>Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response</TI>
<SO>The Journal of Urology</SO>
<YR>2006</YR>
<VL>176</VL>
<NO>4 Pt 1</NO>
<PG>1349-53</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:30:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:30:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16952629"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Meijden-1996" MODIFIED="2010-05-08 11:34:41 -0500" MODIFIED_BY="[Empty name]" NAME="van der Meijden 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-03-15 22:40:28 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meijden AP, Hall RR, Kurth KH, Bouffioux C, Sylvester R</AU>
<TI>Phase II trials in Ta, T1 bladder cancer. The marker tumour concept</TI>
<SO>British Journal of Urology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>5</NO>
<PG>634-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:33:11 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:33:11 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8689102"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Meijden-2000" MODIFIED="2010-06-25 09:43:41 -0500" MODIFIED_BY="[Empty name]" NAME="van der Meijden 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-06-25 09:43:41 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meijden A, Sylvester R, Collette L, Bono A, Ten Kate F</AU>
<TI>The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: A combined analysis of 5 European Organization for Research and Treatment of Cancer trials</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>164</VL>
<NO>5</NO>
<PG>1533-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:34:26 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:34:26 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11025698"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-der-Meijden-2005" MODIFIED="2010-05-08 11:35:24 -0500" MODIFIED_BY="[Empty name]" NAME="van der Meijden 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-03-15 22:41:30 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van der Meijden AP, Sylvester R, Oosterlinck W, Solsona E, Boehle A, Lobel B, et al</AU>
<TI>EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ</TI>
<SO>European Urology</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>3</NO>
<PG>363-71</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:36:21 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:36:21 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15994003"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-2004" MODIFIED="2009-03-15 22:46:21 -0500" MODIFIED_BY="[Empty name]" NAME="Whelan 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-15 22:46:21 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelan P</AU>
<TI>Treatment of superficial bladder cancer: A discussion on intravesical immunotherapy and intravesical chemotherapy</TI>
<SO>European Urology Supplements</SO>
<YR>2004</YR>
<VL>3</VL>
<NO>3</NO>
<PG>70-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Whelan-2007" MODIFIED="2009-03-15 22:46:43 -0500" MODIFIED_BY="[Empty name]" NAME="Whelan 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-03-15 22:46:43 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Whelan P</AU>
<TI>The Treatment of Non-Muscle-Invasive Bladder Cancer with Intravesical Chemotherapy and Immunotherapy</TI>
<SO>European Urology Supplements</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>8</NO>
<PG>568-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjes-1997" MODIFIED="2009-02-08 02:43:05 -0600" MODIFIED_BY="[Empty name]" NAME="Witjes 1997" YEAR="1997">
<REFERENCE MODIFIED="2009-02-08 02:43:05 -0600" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjes JA</AU>
<TI>Current recommendations for the management of bladder cancer. Drug therapy</TI>
<SO>Drugs</SO>
<YR>1997</YR>
<VL>53</VL>
<NO>3</NO>
<PG>404-14</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:42:31 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:42:31 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9074842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjes-2000" MODIFIED="2009-03-15 22:48:27 -0500" MODIFIED_BY="[Empty name]" NAME="Witjes 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-03-15 22:48:27 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjes JA, Mungan NA, Debruyne FM</AU>
<TI>Management of superficial bladder cancer with intravesical chemotherapy: An update</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>1</NO>
<PG>19-21</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:44:08 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:44:08 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10869610"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjes-2004a" MODIFIED="2009-11-30 09:10:30 -0600" MODIFIED_BY="James Tacklind" NAME="Witjes 2004a" YEAR="2004">
<REFERENCE MODIFIED="2009-11-30 09:10:30 -0600" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjes JA, van der Heijden AG, Vriesema JL, Peters GJ, Laan A, Schalken JA</AU>
<TI>Intravesical gemcitabine: a phase 1 and pharmacokinetic study</TI>
<SO>European Urology</SO>
<YR>2004</YR>
<VL>45</VL>
<NO>2</NO>
<PG>182-6</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:44:30 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:44:30 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14734004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjes-2004b" MODIFIED="2010-04-25 08:18:21 -0500" MODIFIED_BY="[Empty name]" NAME="Witjes 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-04-25 08:18:21 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjes JA, Debruyne FM</AU>
<TI>Intravesical chemotherapy for superficial bladder cancer</TI>
<SO>Nature Clinical Practice. Urology</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>2</NO>
<PG>56-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:46:52 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:46:52 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="16474497"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Witjes-2008" MODIFIED="2010-10-06 11:02:55 -0500" MODIFIED_BY="James Tacklind" NAME="Witjes 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-06 11:02:55 -0500" MODIFIED_BY="James Tacklind" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Witjes JA, Hendricksen K</AU>
<TI>Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results</TI>
<SO>European Urology</SO>
<YR>2008</YR>
<VL>53</VL>
<NO>1</NO>
<PG>45-52</PG>
<IDENTIFIERS MODIFIED="2009-08-26 09:41:13 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-26 09:41:13 -0500" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17719169"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-02-09 10:50:44 -0600" MODIFIED_BY="James Tacklind">
<ADDITIONAL_REFERENCES MODIFIED="2011-02-09 10:50:44 -0600" MODIFIED_BY="James Tacklind">
<REFERENCE ID="REF-Alberg-2007" MODIFIED="2009-03-15 22:50:36 -0500" MODIFIED_BY="[Empty name]" NAME="Alberg 2007" TYPE="JOURNAL_ARTICLE">
<AU>Alberg AJ, Kouzis A, Genkinger JM, Gallicchio L, Burke AE, Hoffman SC, et al</AU>
<TI>A prospective cohort study of bladder cancer risk in relation to active cigarette smoking and household exposure to secondhand cigarette smoke</TI>
<SO>American Journal of Epidemiology</SO>
<YR>2007</YR>
<VL>165</VL>
<NO>6</NO>
<PG>660-6</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:47:22 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:47:22 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17204516"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Begg-1996" MODIFIED="2009-02-08 02:49:29 -0600" MODIFIED_BY="[Empty name]" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al</AU>
<TI>Improving the quality of reporting of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<NO>8</NO>
<PG>637-9</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:49:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:49:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="8773637"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Calais-da-Silva-1988" MODIFIED="2009-03-15 22:51:23 -0500" MODIFIED_BY="[Empty name]" NAME="Calais da Silva 1988" TYPE="JOURNAL_ARTICLE">
<AU>Calais da Silva F, Denis L, Bono A, Bollack C, Bouffioux C</AU>
<TI>Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors</TI>
<SO>European Urology</SO>
<YR>1988</YR>
<VL>14</VL>
<NO>3</NO>
<PG>207-9</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:50:40 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:50:40 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3289935"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Cersosimo-1986" MODIFIED="2009-03-15 22:52:09 -0500" MODIFIED_BY="[Empty name]" NAME="Cersosimo 1986" TYPE="JOURNAL_ARTICLE">
<AU>Cersosimo RJ, Hong WK</AU>
<TI>Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<NO>3</NO>
<PG>425-39</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:51:23 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:51:23 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="3005521"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Da-Silva-1992" MODIFIED="2009-03-15 22:52:23 -0500" MODIFIED_BY="[Empty name]" NAME="Da Silva 1992" TYPE="JOURNAL_ARTICLE">
<AU>da Silva FC, Ferrito F, Brandão T, Santos A</AU>
<TI>4'epidoxirubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer</TI>
<SO>European Urology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>1</NO>
<PG>42-4</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:52:12 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:52:12 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="1606981"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2009-03-15 22:55:19 -0500" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>1994</YR>
<VL>309</VL>
<NO>6964</NO>
<PG>1286-91</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:54:26 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:54:26 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7718048"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eleanor-2006" MODIFIED="2010-10-06 10:25:00 -0500" MODIFIED_BY="James Tacklind" NAME="Eleanor 2006" TYPE="OTHER">
<AU>Ray ER, O'Brien TS</AU>
<TI>Aproaches to reducing recurrence in superficial bladder cancer</TI>
<SO>Business briefing: European kidney and urological disease</SO>
<YR>2006</YR>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eto-1994" MODIFIED="2009-03-15 22:53:47 -0500" MODIFIED_BY="[Empty name]" NAME="Eto 1994" TYPE="JOURNAL_ARTICLE">
<AU>Eto H, Oka Y, Ueno K, Nakamura I, Yoshimura K, Arakawa S, et al</AU>
<TI>Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group</TI>
<SO>Cancer Chemotherapy and Pharmacology</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>Suppl</NO>
<PG>S46-51</PG>
<IDENTIFIERS MODIFIED="2009-02-08 02:57:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 02:57:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7994786"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ferlay-2004" MODIFIED="2009-04-20 20:54:01 -0500" MODIFIED_BY="[Empty name]" NAME="Ferlay 2004" TYPE="COMPUTER_PROGRAM">
<AU>Ferlay J, Bray F, Pisani P, Parkin DM</AU>
<TI>GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5</TI>
<YR>2004</YR>
<EN>2.0</EN>
<PB>IARC (International Agency for Research on Cancer) Press Lyon</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herr-1997" MODIFIED="2010-10-06 10:32:18 -0500" MODIFIED_BY="James Tacklind" NAME="Herr 1997" TYPE="JOURNAL_ARTICLE">
<AU>Herr HW</AU>
<TI>Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients</TI>
<SO>World Journal of Urology</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>2</NO>
<PG>84-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:00:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:00:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="9144896"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2009-10-06 08:11:24 -0500" MODIFIED_BY="James Tacklind" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal (Clinical research ed.)</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:01:07 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:01:07 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12958120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2011-02-09 10:50:44 -0600" MODIFIED_BY="James Tacklind" NAME="Higgins 2008" TYPE="OTHER">
<AU>Higgins JPT, Green S</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions, Version 5.0.2</TI>
<SO>http://www.cochrane-handbook.org/ (accessed 9 February 2011)</SO>
<YR>updated September 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jankovic-2007" MODIFIED="2009-02-08 03:03:06 -0600" MODIFIED_BY="[Empty name]" NAME="Jankovic 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jankovi&#263; S, Radosavljevi&#263; V</AU>
<TI>Risk factors for bladder cancer</TI>
<SO>Tumori</SO>
<YR>2007</YR>
<VL>93</VL>
<NO>1</NO>
<PG>4-12</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:02:04 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:02:04 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17455864"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kamat-2000" MODIFIED="2009-02-08 03:03:29 -0600" MODIFIED_BY="[Empty name]" NAME="Kamat 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kamat A, Lamm D</AU>
<TI>Intravesical therapy for bladder cancer</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>55</VL>
<PG>161-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:03:29 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:03:29 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10688071"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Koga-2004" MODIFIED="2011-01-27 20:21:30 -0600" MODIFIED_BY="[Empty name]" NAME="Koga 2004" TYPE="JOURNAL_ARTICLE">
<AU>Koga H, Kuroiwa K, Yamaguchi A, Osada Y, Tsuneyoshi M, Naito S</AU>
<TI>A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder</TI>
<SO>The Journal of Urology</SO>
<YR>2004</YR>
<VL>171</VL>
<PG>153-7</PG>
<IDENTIFIERS MODIFIED="2011-01-27 20:20:44 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-01-27 20:20:44 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="14665865"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lebret-2000" MODIFIED="2009-03-15 23:02:45 -0500" MODIFIED_BY="[Empty name]" NAME="Lebret 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, et al</AU>
<TI>Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations</TI>
<SO>The Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>1</NO>
<PG>63-7</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:03:40 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:03:40 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="10604315"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-1996" MODIFIED="2009-03-01 03:50:05 -0600" MODIFIED_BY="[Empty name]" NAME="Lefebvre 1996" TYPE="CONFERENCE_PROC">
<AU>Lefebvre C, McDonald S</AU>
<TI>Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE</TI>
<SO>Fourth International Cochrane Colloquium, Adelaide Australia, 20-24 October</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lutzeyer-1982" MODIFIED="2009-03-15 23:04:45 -0500" MODIFIED_BY="[Empty name]" NAME="Lutzeyer 1982" TYPE="JOURNAL_ARTICLE">
<AU>Lutzeyer W, Rubben H, Dahm H</AU>
<TI>Prognostic parameters in superficial bladder cancer: an analysis of 315 cases</TI>
<SO>The Journal of Urology</SO>
<YR>1982</YR>
<VL>127</VL>
<NO>2</NO>
<PG>250-2</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:06:23 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:06:23 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7062375"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Mitsumori-2004" MODIFIED="2009-02-08 03:06:51 -0600" MODIFIED_BY="[Empty name]" NAME="Mitsumori 2004" TYPE="JOURNAL_ARTICLE">
<AU>Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C, et al</AU>
<TI>Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection</TI>
<SO>BJU international</SO>
<YR>2004</YR>
<VL>94</VL>
<NO>3</NO>
<PG>317-21</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:06:51 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:06:51 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="15291859"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morales-1976" MODIFIED="2009-03-15 23:04:37 -0500" MODIFIED_BY="[Empty name]" NAME="Morales 1976" TYPE="JOURNAL_ARTICLE">
<AU>Morales A, Eidinger D, Bruce AW</AU>
<TI>Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors</TI>
<SO>The Journal of Urology</SO>
<YR>1976</YR>
<VL>116</VL>
<PG>180-3</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:07:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:07:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11905917"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Morgan-2002" MODIFIED="2009-03-15 23:05:27 -0500" MODIFIED_BY="[Empty name]" NAME="Morgan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Morgan BE, Salup R, Morgan MB</AU>
<TI>Differential C-erbB-2 and VEGF expression following BCG immunotherapy in superficial papillary transitional cell carcinoma of the bladder</TI>
<SO>Urologic Oncology</SO>
<YR>2002</YR>
<VL>7</VL>
<NO>2</NO>
<PG>67-72</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:09:18 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:09:18 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12474525"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Naoe-2007" MODIFIED="2010-10-06 10:34:03 -0500" MODIFIED_BY="James Tacklind" NAME="Naoe 2007" TYPE="JOURNAL_ARTICLE">
<AU>Naoe M, Ogawa Y, Takeshita K, Morita J, Iwamoto S, Miyazaki A, et al</AU>
<TI>Bacillus Calmette-Guérin-pulsed dendritic cells stimulate natural killer T cells and gammadeltaT cells</TI>
<SO>International Journal of Urology</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>6</NO>
<PG>532-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:10:07 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:10:07 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17593099"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Oosterlinck-2002" MODIFIED="2009-03-15 23:07:11 -0500" MODIFIED_BY="[Empty name]" NAME="Oosterlinck 2002" TYPE="JOURNAL_ARTICLE">
<AU>Oosterlinck W, Lobel B, Jakse G, Malmstrom PU, Stöckle M, Sternberg C, et al</AU>
<TI>Guidelines on bladder cancer</TI>
<SO>European Urology</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>2</NO>
<PG>105-12</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:10:50 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:10:50 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="12074395"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parekh-2006" MODIFIED="2009-03-15 23:08:01 -0500" MODIFIED_BY="[Empty name]" NAME="Parekh 2006" TYPE="JOURNAL_ARTICLE">
<AU>Parekh DJ, Bochner BH, Dalbagni G</AU>
<TI>Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>35</NO>
<PG>5519-27</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:13:32 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:13:32 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17158537"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parkin-2002" MODIFIED="2009-02-08 03:13:54 -0600" MODIFIED_BY="[Empty name]" NAME="Parkin 2002" TYPE="BOOK">
<AU>Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB</AU>
<SO>Cancer incidence in five continents</SO>
<YR>2002</YR>
<PB>IARC (International Agency for Research on Cancer) Scientific Publications</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Popert-1994" MODIFIED="2009-03-15 23:08:55 -0500" MODIFIED_BY="[Empty name]" NAME="Popert 1994" TYPE="JOURNAL_ARTICLE">
<AU>Popert RJ, Goodall J, Coptcoat MJ, Thompson PM, Parmar MK, Masters JR</AU>
<TI>Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin</TI>
<SO>British Journal of Urology</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>2</NO>
<PG>195-8</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:14:37 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:14:37 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="7921938"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2010-07-19 09:38:40 -0500" MODIFIED_BY="James Tacklind" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shelley-2000" MODIFIED="2010-10-06 10:36:15 -0500" MODIFIED_BY="James Tacklind" NAME="Shelley 2000" TYPE="COCHRANE_REVIEW">
<AU>Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M</AU>
<TI>Intravesical Bacillus Calmette-Guérin in Ta and T1 bladder cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-03-07 02:55:59 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-03-07 02:55:59 -0600" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001986"/>
<IDENTIFIER MODIFIED="2009-03-07 02:39:03 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="11034738"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-der-Meijden-2006" MODIFIED="2010-05-08 11:36:38 -0500" MODIFIED_BY="[Empty name]" NAME="van der Meijden 2006" TYPE="JOURNAL_ARTICLE">
<AU>van der Meijden AP</AU>
<TI>Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer</TI>
<SO>TheScientificWorldJournal</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>6</NO>
<PG>2611-6</PG>
<IDENTIFIERS MODIFIED="2009-02-08 03:21:57 -0600" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-02-08 03:21:57 -0600" MODIFIED_BY="[Empty name]" TYPE="PUBMED" VALUE="17619738"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2010" MODIFIED="2011-01-27 20:24:23 -0600" MODIFIED_BY="[Empty name]" NAME="Wilson 2010" TYPE="JOURNAL_ARTICLE">
<AU>Wilson JRF, Turney BW, LeMonnier K, Crew JP</AU>
<TI>A comparison of two BCG instillation regimens for non-muscle invasive bladder cancer: A retrospective cohort analysis of side effect profiles</TI>
<SO>British Journal of Medical and Surgical Urology</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>241-8</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-03-16 10:25:35 -0500" MODIFIED_BY="James Tacklind">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-03-16 10:25:35 -0500" MODIFIED_BY="James Tacklind" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-04-25 08:43:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2005">
<CHAR_METHODS MODIFIED="2009-11-27 19:07:47 -0600" MODIFIED_BY="[Empty name]">
<P>Randomised prospective study. Method not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 09:23:10 -0600" MODIFIED_BY="[Empty name]">
<P>High-risk participants</P>
<P>Geographic region: Hong Kong, China</P>
<P>N = 209 (BCG, n = 107; EPI, n = 102)</P>
<P>Inclusion: superficial bladder cancer (Ta or T1) with one or more of the relevant criteria (stage &gt; a, grade &gt; 1, size &gt; 1 cm, multiple or recurrent tumours).</P>
<P>Exclusion: Those with carcinoma in situ or previous intravesical treatment were excluded.</P>
<P>Mean age (range): 69.9 years (24 to 92)</P>
<P>Median follow up (range): 23 months (0 to 125) for recurrence, 47 months (0 to 127) for progression and 61 months (3 to 127) for survival.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-03 03:11:08 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>BCG: 81 mg Connaught strain BCG diluted with 50 ml saline was administered intravesically and retained for 2 hours. The treatment was given as an induction course weekly for 6 weeks and then a maintenance course monthly for 10 months (a total of 16 instillations).</LI>
<LI>EPI: 50 mg of the agent diluted with 50 ml saline was administered intravesically and retained for 2 hours. The treatment was given weekly for 4 weeks, monthly for 5 months and then thrice-monthly for 6 months (a total of 11 instillations).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-04-25 08:43:01 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Recurrence</LI>
<LI>Progression</LI>
<LI>Survival</LI>
<LI>Metastasis</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-29 09:23:22 -0600" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-16 10:25:35 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Melekos-1993">
<CHAR_METHODS MODIFIED="2009-11-29 08:20:31 -0600" MODIFIED_BY="[Empty name]">
<P>Prospective, quasi-randomised controlled study. Randomised on a 2:2:1 basis within strata and according to data of birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-14 10:05:23 -0500" MODIFIED_BY="James Tacklind">
<P>Low, intermediate and high-risk participants</P>
<P>Geographic region: Greece</P>
<P>N = 161 (BCG, n = 62; EPI, n = 68; TUR alone, n = 32)</P>
<P>Inclusion: superficial transitional cell carcinoma of bladder (stages Ta and T1 and Grades 1 to 3).</P>
<P>Exclusion: Multifocal carcinoma in situ, another cancer or history of another cancer outside the bladder, previous local or systemic chemotherapy or radiotherapy.</P>
<P>Mean age (range): BCG: 67.1, EPI: 65 (NA)</P>
<P>Mean follow up: 32.9 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 09:53:45 -0600" MODIFIED_BY="James Tacklind">
<OL>
<LI>BCG: intravesical 150 mg of Pasteur-F strain immune BCG suspended in 50 mL sterile saline and retained in the bladder for 1.5 hours. Started 14 days after TUR and included an initial 6-week course of instillations and, a single maintenance dose at every 3 months during the first 2 years. For high risk for recurrence, one separate 4 week course at month 6 of follow up (a total of 14 or 18 instillations).</LI>
<LI>EPI: intravesical 50 mg of epirubicin suspended in 50 ml sterile saline and retained in the bladder for 1.5 hours. Started 14 days after TUR and included an initial 6-week course of instillations and, a single maintenance dose at every 3 months during the first 2 years. For high risk for recurrence, one separate 4-week course at month 6 of follow up (a total of 14 or 18 instillations).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-16 10:25:35 -0500" MODIFIED_BY="James Tacklind">
<OL>
<LI>Recurrence</LI>
<LI>Progression</LI>
<LI>Local urothelial spread</LI>
<LI>Muscle infiltration</LI>
<LI>Local side effects</LI>
<LI>Systemic side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-29 09:24:22 -0600" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Patients with stage Ta, T1 bladder cancer can be classified. into 1 of 3 different risk groups according to prognostic factors. &amp;#161;&amp;#176;All risk&amp;#161;&amp;#177; means is that low, intermediate and high risk of prognostic factors.&lt;/p&gt;" NOTES_MODIFIED="2010-01-29 09:24:22 -0600" NOTES_MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-14 10:08:44 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Melekos-1996a">
<CHAR_METHODS MODIFIED="2009-11-27 19:09:52 -0600" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised prospective study. Randomised according to date of birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-02 07:36:57 -0600" MODIFIED_BY="[Empty name]">
<P>Low-, intermediate- and high-risk participants</P>
<P>Geographic region: Greece</P>
<P>N = 106 (BCG, n = 52; EPI, n = 54)</P>
<P>Inclusion: completely resectable multiple papillary superficial bladder tumours at stage Ta or T1 and grades 1 to 3</P>
<P>Exclusion: solitary neoplasms, multifocal carcinoma in situ, another cancer or history of another cancer outside the bladder, previous systemic chemotherapy or radiotherapy</P>
<P>Mean age: BCG, 65.4; EPI, 67.1</P>
<P>Mean follow up: 35.1 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-14 10:08:44 -0500" MODIFIED_BY="James Tacklind">
<OL>
<LI>BCG: to receive 150 mg of Pasteur strain immune BCG suspended in 50 mL sterile saline which were retained in the bladder for 1.5 hours. Started 7 to 14 days after TUR and included an initial 6-week course of instillations and, a single maintenance dose at every 3 months until the end of the second year, plus a separate 4-week course at month 6 of follow up (a total instillations from 14 to17).</LI>
<LI>EPI: to receive either 50 mg of epirubicin suspended in 50 mL sterile saline which were retained in the bladder for 1.5 hours. Started within 2 days after TUR and retained in the bladder for 30 to 45 minutes, followed by 4 weekly treatments and, I0 monthly treatments during the first year and at every 3 months until the end of the second year (a total instillations from 15 to 19).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-30 10:11:21 -0600" MODIFIED_BY="James Tacklind">
<OL>
<LI>Recurrence</LI>
<LI>Progression</LI>
<LI>Muscle invasion</LI>
<LI>Metastasis</LI>
<LI>Local toxicity</LI>
<LI>Systemic toxicity</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-29 09:25:09 -0600" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-14 10:01:06 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Melekos-1996b">
<CHAR_METHODS MODIFIED="2009-11-27 19:10:49 -0600" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised prospective study. Randomised according to date of birth.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-14 10:01:06 -0500" MODIFIED_BY="James Tacklind">
<P>High-risk participants</P>
<P>Geographic region: Greece</P>
<P>N = 132 (BCG, n = 58; EPI, n = 61 (13 eligible patients were excluded))</P>
<P>Inclusion: recurrent and/or multiple papillary superficial bladder tumours at stages Ta and T1 of any grade</P>
<P>Exclusion: solitary - primary neoplasms, tumours at stage &gt;T1, multifocal carcinoma in situ, another cancer or history of another cancer outside the bladder, previous systemic chemotherapy or radiotherapy</P>
<P>Mean age (year): BCG 65.3; EPI 67.2</P>
<P>Median follow up: 43 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-11-30 10:21:00 -0600" MODIFIED_BY="James Tacklind">
<OL>
<LI>BCG: Received an initial 6 week induction course of instillations (BCG Tice strain, 5×10<SUP>8</SUP> colony forming units in 50 mL saline and retained in the bladder for 1.5 hours), the first was administered within 10 days after TUR and received in addition a single maintenance dose at every 3 months until the end of the second year of follow up. For high risk patients, 3 weekly course of BCG instillation were administered at month 6 (a total of 16 instillations).</LI>
<LI>EPI: Received an 4 week induction course of instillations (50 mg epirubicin in 50 mL saline and retained in the bladder for 1.5 hours), the first was administered within 2 days after TUR and received in addition a single maintenance dose at every 3 months until the end of the second year of follow up. For high risk patients, 3-week course of EPI instillation were administered at month 3 and 6 (a total of 16 instillations).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-30 10:21:50 -0600" MODIFIED_BY="James Tacklind">
<OL>
<LI>Recurrence</LI>
<LI>Progression</LI>
<LI>Muscle infiltration</LI>
<LI>Metastasis</LI>
<LI>Local toxicity</LI>
<LI>Systemic toxicity</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-29 09:25:57 -0600" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-03-14 10:01:22 -0500" MODIFIED_BY="James Tacklind" STUDY_ID="STD-Sylvester-2010">
<CHAR_METHODS MODIFIED="2010-04-25 08:33:32 -0500" MODIFIED_BY="[Empty name]">
<P>A multi center, randomised, prospective, controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-03-14 10:01:22 -0500" MODIFIED_BY="James Tacklind">
<P>Intermediate- and high-risk participants</P>
<P>Geographic region: Europe</P>
<P>N = 957 (BCG, n = 320; EPI, n = 318; BCG with the same dose plus isoniazid (300 mg), n = 319)</P>
<P>Inclusion: intermediate or high risk superficial bladder tumours, single or multiple tumours, primary or recurrent, completely resectable stage Ta to T1, grades 1 to 3, biopsy-diagnosed transitional carcinoma of the bladder.</P>
<P>Exclusion: a solitary primary tumour; carcinoma in situ; stage T2 or higher tumours; age &gt;85 yr; WHO performance status 3 or 4; previous treatment with doxorubicin, epirubicin, or BCG; and intravesical treatment during the previous 3 months</P>
<P>Mean age (range): BCG, 66 (interquartile range from 60 to 72); EPI, 67 (interquartile range from 60 to 73)</P>
<P>Median follow up: 110 months (maximum follow-up of 172 months).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-04-25 09:08:21 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>BCG: BCG (Tice-strain) - 5×10<SUP>8</SUP> colony forming units weekly for 6 consecutive weeks starting 7 to 15 days after transurethral resection, followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36 (a total of 27 instillations).</LI>
<LI>EPI: 50 mg epirubicin in 50 mL of saline weekly for 6 consecutive weeks starting within 24 hours after transurethral resection, followed by 3 weekly instillations at months 3, 6, 12, 18, 24, 30 and 36 (a total of 27 instillations).</LI>
</OL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-25 09:46:32 -0500" MODIFIED_BY="[Empty name]">
<OL>
<LI>Recurrence</LI>
<LI>Progression</LI>
<LI>Metastasis</LI>
<LI>Overall survival</LI>
<LI>Disease-specific survival</LI>
<LI>Drug-induced cystitis</LI>
<LI>Haematuria</LI>
<LI>Systemic effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-06-25 09:46:23 -0500" MODIFIED_BY="[Empty name]">
<P>Data on adverse effects were first obtained from the secondary reference which consisted of a median follow-up period of 46.8 months (van der Meijden et al); subsequent long-term efficacy data were reported in the primary reference.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-04-25 08:28:22 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-04-25 08:22:19 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addeo-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-25 08:22:19 -0500" MODIFIED_BY="[Empty name]">
<P>This trial compared the therapeutic efficacy and toxicity of intravescical infusions of gemcitabine (GEM) with mitomycin (MMC) in patients with a recurrent superficial bladder cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Akaza-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ali_x002d_EI_x002d_Dein-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial intravesical epirubicin in the first 3 years and intravesical BCG in the next 3 years.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ali_x002d_El_x002d_Dein-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with alternating BCG and EPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Badalament-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barton-Grossman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:32:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Beltrami-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:32:06 -0500" MODIFIED_BY="[Empty name]">
<P>This study was to evaluate if there was a significant association between intravesical immuno- or chemotherapy and the increase of PSA serum level.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bilen-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with alternating BCG and EPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bismarck-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bohle-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial comment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bono-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bono-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bono-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borden-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Borkowski-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Botteman-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bradner-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brassell-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brausi-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brausi-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bulbul-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:28:30 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cai-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:28:30 -0500" MODIFIED_BY="[Empty name]">
<P>This trial compared BCG with alternating BCG and EPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Canda-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study evaluated the outcome of patients with mucosal prostatic urethral TCC who were managed conservatively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Catanzaro-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared BCG with doxorubicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cervenakov-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared Alpha 2-b interferon with farmarubicin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chung-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cindolo-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised, Insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corica-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalbagni-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Damianov-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparative Study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Damianov-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Reijke-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reiew</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Reijke-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with EPI for carcinoma in situ of the bladder.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Reijke-2005b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Denis-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Overview, Insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Di-Stasi-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with alternating BCG and mitomycin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Djulbegovic-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doehn-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-25 08:28:22 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duchek-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-25 08:28:22 -0500" MODIFIED_BY="[Empty name]">
<P>This trial compared BCG with the combination of EPI and interferon-alpha2b.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duque-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Overview</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-El_x002d_Sebaie-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Erol-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with alternating BCG and EPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fradet-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gasion-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goldberg-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gontero-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Grasso-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised, insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gschwend-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gwynn-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gwynn-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hall-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hinotsu-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hong-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huncharek-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reviews</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huncharek-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Huncharek-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta-Analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:19:44 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Iida-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:19:44 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Josephson-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kausch-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kondo-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konukoglu-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study assessed glycosaminoglycan inpatients with superficial bladder cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konukoglu-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study assessed urinary zinc levels in patients with superficial bladder cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koya-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kumar-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kurth-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamm-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamm-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamm-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lamm-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lerner-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lockyer-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lodde-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study assessed the influence of intravesical instillation on performance of uCYT+ test.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lorusso-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malmstr_x00f6_m-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malmstr_x00f6_m-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malmstr_x00f6_m-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Martinez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McFarlane-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mehraban-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Melekos-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merkle-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial was in abstract form only and had insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mitropoulos-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morganstern-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Munro-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Newling-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nilsson-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-O_x0027_Donnell-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ojea-Calvo-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okeke-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Onrust-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oosterlinck-2001a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Evaluation Studies.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oosterlinck-2001b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oosterlinck-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oosterlinck-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozen-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pagliaro-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Patard-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pavone_x002d_Macaluso-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pegoraro-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparative Study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perabo-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pham-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:34:57 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Racioppi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:34:57 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Raitanen-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised, insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roggia-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comparative Study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Romics-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared BCG with alternating interferon and EPI.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Santhanam-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scher-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Serretta-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shelley-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Systematic Reviews</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-04-25 08:22:48 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shelley-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-04-25 08:22:48 -0500" MODIFIED_BY="[Empty name]">
<P>a systematic review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Skinner-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soloway-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Soloway-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Comment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:39:06 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stankovi_x0107_-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:39:06 -0500" MODIFIED_BY="[Empty name]">
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sylvester-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Earlier rport of De Reijke 2005a.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sylvester-2005a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta-Analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sylvester-2005b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:24:33 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sylvester-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:24:33 -0500" MODIFIED_BY="[Empty name]">
<P>Editorial comment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takahashi-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised, Insufficient data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Takashi-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trinchieri-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tsujikawa-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study compared mitomycin-C with adriamycin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uekado-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Heijden-2003a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Heijden-2003b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Heijden-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial studied the ablative activity of intravesical apaziquone on superficial bladder cancer.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Meijden-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Meijden-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-der-Meijden-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Guideline</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Whelan-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witjes-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witjes-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witjes-2004a">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial investigated the use of three dose levels of gemcitabine when given intravesically in humans for safety and pharmacokinetic research.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Witjes-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-26 09:41:43 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Witjes-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-26 09:41:43 -0500" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-06-25 09:41:07 -0500" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-25 09:40:52 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 09:23:44 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 09:24:34 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>According to dates of birth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 09:25:25 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>According to dates of birth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 09:26:10 -0600" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>According to dates of birth</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-25 09:40:52 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>Randomization by the minimization technique</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-06-25 09:41:07 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-04 09:14:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-04 09:15:19 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-04 09:16:23 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-04 09:17:33 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-25 09:41:07 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>Central randomization at the European Organization for Research and Treatment of Cancer Genito-Urinary Group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-05-08 12:27:12 -0500" MODIFIED_BY="Joey Kwong" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-04 02:33:35 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-04 02:33:57 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-04 02:34:52 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-10-04 02:35:21 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-04-25 08:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-05-08 12:27:12 -0500" MODIFIED_BY="Joey Kwong" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-04 07:58:38 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>No incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-04 07:59:37 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>No incomplete outcome data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 10:17:35 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>6/52 eligible patients were excluded from BCG group and 6/54 were excluded from EPI group, due to protocol violation, loss to follow up, incorrect T category or cell type, or other reasons.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-30 10:22:13 -0600" MODIFIED_BY="James Tacklind" RESULT="YES" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>13 eligible patients were excluded due to protocol violation, loss to follow up, incorrect T category or cell type, or other reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-25 08:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>39/320 eligible patients were excluded from BCG group and 39/318 were excluded from EPI group, due to the fact that they were randomized before confirmation of histological stage and grade.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-05-08 12:27:12 -0500" MODIFIED_BY="Joey Kwong" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:40:18 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:42:50 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:45:34 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:47:25 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 08:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>No selective reporting</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-05-08 12:27:12 -0500" MODIFIED_BY="Joey Kwong" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:40:30 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Cheng-2005">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:42:48 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1993">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:45:44 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1996a">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-29 08:47:27 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Melekos-1996b">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-25 08:55:11 -0500" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sylvester-2010">
<DESCRIPTION>
<P>No other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-03-12 21:02:17 -0600" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-06 10:37:35 -0500" MODIFIED_BY="James Tacklind" NO="1">
<NAME>Frequency of tumour recurrence (relapse)</NAME>
<DICH_OUTCOME CHI2="3.3544818743226568" CI_END="0.7921583958193151" CI_START="0.6007668443266004" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6898568689686231" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="289" I2="0.0" I2_Q="29.092094384861795" ID="CMP-001.01" LOG_CI_END="-0.10118797049088445" LOG_CI_START="-0.2212940435860044" LOG_EFFECT_SIZE="-0.16124100703844443" METHOD="MH" MODIFIED="2010-04-25 10:05:25 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5003468450549712" P_Q="0.24407524020248994" P_Z="1.421423472883918E-7" Q="2.8205599681018048" RANDOM="NO" SCALE="30.67" SORT_BY="EFFECT_SIZE" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="549" TOTAL_2="562" WEIGHT="100.0" Z="5.262457733940531">
<NAME>BCG strains</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.7537771029545651" CI_START="0.37745289179386865" DF="0" EFFECT_SIZE="0.5333998005982054" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="59" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.12275705899508348" LOG_CI_START="-0.42313724300329586" LOG_EFFECT_SIZE="-0.2729471509991897" MODIFIED="2010-04-25 10:02:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.6813863224174204E-4" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="107" WEIGHT="20.154041638502523" Z="3.561929941600953">
<NAME>Connaught BCG</NAME>
<DICH_DATA CI_END="0.7537771029545651" CI_START="0.37745289179386865" EFFECT_SIZE="0.5333998005982054" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="59" LOG_CI_END="-0.12275705899508348" LOG_CI_START="-0.42313724300329586" LOG_EFFECT_SIZE="-0.2729471509991897" MODIFIED="2010-04-25 10:02:31 -0500" MODIFIED_BY="[Empty name]" ORDER="45" O_E="0.0" SE="0.1764448069923153" STUDY_ID="STD-Cheng-2005" TOTAL_1="102" TOTAL_2="107" VAR="0.0311327699145554" WEIGHT="20.154041638502523"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.023469497037591915" CI_END="1.0986734030888445" CI_START="0.5560637079487998" DF="1" EFFECT_SIZE="0.781621651661665" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="49" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.04086861115311956" LOG_CI_START="-0.2548754486596667" LOG_EFFECT_SIZE="-0.10700341875327363" MODIFIED="2010-04-23 19:15:19 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8782424847488539" P_Z="0.1561111956947333" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="16.61829213022471" Z="1.418272590914145">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="1.2526572678700651" CI_START="0.45975784930244934" EFFECT_SIZE="0.758893280632411" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.09783226250773919" LOG_CI_START="-0.3374708474522759" LOG_EFFECT_SIZE="-0.11981929247226833" MODIFIED="2009-11-27 20:14:03 -0600" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.25569920157565906" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="0.06538208168642952" WEIGHT="7.5354451519137475"/>
<DICH_DATA CI_END="1.272767728535132" CI_START="0.503442104653773" EFFECT_SIZE="0.8004778972520908" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.10474915509170295" LOG_CI_START="-0.29805046567657" LOG_EFFECT_SIZE="-0.09665065529243354" MODIFIED="2009-11-29 02:07:29 -0600" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.2366064911295634" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.05598263164464416" WEIGHT="9.082846978310963"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.48340256729253717" CI_END="0.8467181922803309" CI_START="0.6048018390323241" DF="1" EFFECT_SIZE="0.7156093346465437" ESTIMABLE="YES" EVENTS_1="129" EVENTS_2="181" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="-0.07226110903419954" LOG_CI_START="-0.2183868969374449" LOG_EFFECT_SIZE="-0.14532400298582226" MODIFIED="2010-04-25 09:50:05 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4868851649496775" P_Z="9.682256918234015E-5" STUDIES="2" TAU2="0.0" TOTAL_1="339" TOTAL_2="340" WEIGHT="63.22766623127278" Z="3.898419519626446">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="0.8410203009718975" CI_START="0.575478453056706" EFFECT_SIZE="0.6956932239087806" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="147" LOG_CI_END="-0.07519352085647339" LOG_CI_START="-0.23997093249249898" LOG_EFFECT_SIZE="-0.1575822266744862" MODIFIED="2010-04-25 09:49:59 -0500" MODIFIED_BY="[Empty name]" ORDER="34" O_E="0.0" SE="0.09679106725634384" STUDY_ID="STD-Sylvester-2010" TOTAL_1="281" TOTAL_2="279" VAR="0.009368510700622078" WEIGHT="51.628782276379006"/>
<DICH_DATA CI_END="1.15584492107741" CI_START="0.5596196760616847" EFFECT_SIZE="0.8042596348884381" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" LOG_CI_END="0.06289956899948891" LOG_CI_START="-0.2521070242467038" LOG_EFFECT_SIZE="-0.09460372762360743" MODIFIED="2009-11-29 02:07:50 -0600" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.18503643218059837" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.03423848123412518" WEIGHT="11.598883954893775"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-04-26 09:37:18 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Disease progression by stage (&#8805; stage T2)</NAME>
<DICH_OUTCOME CHI2="0.0898974286516561" CI_END="1.1317704670669428" CI_START="0.5370336668867562" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.779614548352644" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.053758357069530735" LOG_CI_START="-0.2699984873268463" LOG_EFFECT_SIZE="-0.1081200651286578" METHOD="MH" MODIFIED="2010-04-26 09:37:18 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9990195736297942" P_Q="0.9637715050038409" P_Z="0.19050803003499975" Q="0.07380208209037614" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="549" TOTAL_2="562" WEIGHT="100.0" Z="1.3090777064706631">
<NAME>BCG strains</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9844300766178407" CI_START="0.37121973783799567" DF="0" EFFECT_SIZE="0.8582887700534759" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.29763580071154533" LOG_CI_START="-0.43036894030276157" LOG_EFFECT_SIZE="-0.0663665697956081" MODIFIED="2010-04-26 09:37:18 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.7208301338314862" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="107" WEIGHT="18.774326150176076" Z="0.3573495590032136">
<NAME>Connaught BCG</NAME>
<DICH_DATA CI_END="1.9844300766178407" CI_START="0.37121973783799567" EFFECT_SIZE="0.8582887700534759" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.29763580071154533" LOG_CI_START="-0.43036894030276157" LOG_EFFECT_SIZE="-0.0663665697956081" MODIFIED="2010-04-26 09:37:18 -0500" MODIFIED_BY="[Empty name]" ORDER="150" O_E="0.0" SE="0.42763358855339134" STUDY_ID="STD-Cheng-2005" TOTAL_1="102" TOTAL_2="107" VAR="0.1828704860590512" WEIGHT="18.774326150176076"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0016863649971974896" CI_END="1.6426982957692506" CI_START="0.3279303858092842" DF="1" EFFECT_SIZE="0.73395550675764" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.21555780657904225" LOG_CI_START="-0.48421834003116204" LOG_EFFECT_SIZE="-0.13433026672605985" MODIFIED="2010-04-26 09:37:16 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9672437845210389" P_Z="0.45176467974182855" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="22.064582773413512" Z="0.7524763057217856">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="2.433146821979589" CI_START="0.21331205134958692" EFFECT_SIZE="0.7204301075268817" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.3861683161037254" LOG_CI_START="-0.6709846078099427" LOG_EFFECT_SIZE="-0.14240814585310865" MODIFIED="2010-04-23 18:28:33 -0500" MODIFIED_BY="[Empty name]" ORDER="164" O_E="0.0" SE="0.6209768604982586" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.3856122612742738" WEIGHT="10.084886550345379"/>
<DICH_DATA CI_END="2.181718980861131" CI_START="0.2546313836865707" EFFECT_SIZE="0.7453416149068323" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.3387988099915217" LOG_CI_START="-0.5940880699599715" LOG_EFFECT_SIZE="-0.1276446299842249" MODIFIED="2010-04-23 18:28:34 -0500" MODIFIED_BY="[Empty name]" ORDER="165" O_E="0.0" SE="0.5479823711480388" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="0.30028467908902695" WEIGHT="11.979696223068132"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.014480669827518815" CI_END="1.2549567010703448" CI_START="0.4745064371462214" DF="1" EFFECT_SIZE="0.7716767671750038" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="34" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.09862874190421463" LOG_CI_START="-0.32375789156520185" LOG_EFFECT_SIZE="-0.1125645748304936" MODIFIED="2010-04-25 09:50:43 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9042172635936504" P_Z="0.29618605898244343" STUDIES="2" TAU2="0.0" TOTAL_1="339" TOTAL_2="340" WEIGHT="59.16109107641042" Z="1.0446472265974573">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="1.80445685544456" CI_START="0.3003677216747804" EFFECT_SIZE="0.7362068965517241" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.2563465025405212" LOG_CI_START="-0.5223467396163481" LOG_EFFECT_SIZE="-0.13300011853791344" MODIFIED="2010-04-23 18:41:50 -0500" MODIFIED_BY="[Empty name]" ORDER="166" O_E="0.0" SE="0.45740826503665977" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.2092223209238472" WEIGHT="17.04507119582636"/>
<DICH_DATA CI_END="1.4019502726938486" CI_START="0.4407048964676036" EFFECT_SIZE="0.7860320284697508" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="24" LOG_CI_END="0.14673260943829447" LOG_CI_START="-0.35585212421881335" LOG_EFFECT_SIZE="-0.10455975739025943" MODIFIED="2010-04-25 09:50:37 -0500" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.29522076038474004" STUDY_ID="STD-Sylvester-2010" TOTAL_1="281" TOTAL_2="279" VAR="0.0871552973621441" WEIGHT="42.11601988058406"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-04-26 10:38:31 -0500" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Mortality</NAME>
<DICH_OUTCOME CHI2="1.8913008312012984" CI_END="1.0399862037144978" CI_START="0.7086669029072612" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8584892556419289" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="147" I2="47.126338470182475" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.017027578058005047" LOG_CI_START="-0.14955784975632214" LOG_EFFECT_SIZE="-0.06626513584915855" METHOD="MH" MODIFIED="2010-04-26 10:38:31 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.16905549507520679" P_Q="1.0" P_Z="0.1189283714810833" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="383" TOTAL_2="386" WEIGHT="99.99999999999999" Z="1.5592874046553873">
<NAME>Overall mortality</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4699614958009355" CI_START="0.7486197024771547" EFFECT_SIZE="1.0490196078431373" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="41" LOG_CI_END="0.16730595897933784" LOG_CI_START="-0.12573874713275363" LOG_EFFECT_SIZE="0.0207836059232921" MODIFIED="2010-04-26 10:38:31 -0500" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.1721359109649327" STUDY_ID="STD-Cheng-2005" TOTAL_1="102" TOTAL_2="107" VAR="0.029630771843727234" WEIGHT="27.33590484819183"/>
<DICH_DATA CI_END="0.9937761890643679" CI_START="0.6229511924896469" EFFECT_SIZE="0.7868125965218559" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="106" LOG_CI_END="-0.002711413187022485" LOG_CI_START="-0.20554597848171932" LOG_EFFECT_SIZE="-0.10412869583437094" MODIFIED="2010-04-26 09:47:16 -0500" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.11914602770139623" STUDY_ID="STD-Sylvester-2010" TOTAL_1="281" TOTAL_2="279" VAR="0.01419577591702188" WEIGHT="72.66409515180816"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.658735978309973" CI_END="3.795375108668691" CI_START="0.23405424488253765" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9425092334324529" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="26" I2="82.32820891745054" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.5792547050205186" LOG_CI_START="-0.6306834779616837" LOG_EFFECT_SIZE="-0.025714386470582464" METHOD="MH" MODIFIED="2010-04-26 10:06:55 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.017368659398709574" P_Q="1.0" P_Z="0.9336059739027981" Q="0.0" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8321206989183796" TOTALS="YES" TOTAL_1="383" TOTAL_2="386" WEIGHT="100.0" Z="0.08330883689059851">
<NAME>Disease-specific mortality</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.687026205347238" CI_START="0.8097677095095724" EFFECT_SIZE="1.9481792717086834" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.6708973816844701" LOG_CI_START="-0.09163954525272613" LOG_EFFECT_SIZE="0.289628918215872" MODIFIED="2010-04-26 10:06:11 -0500" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.4479179655015737" STUDY_ID="STD-Cheng-2005" TOTAL_1="102" TOTAL_2="107" VAR="0.20063050381906897" WEIGHT="48.91092308529583"/>
<DICH_DATA CI_END="1.0214805447365514" CI_START="0.2165426684603451" EFFECT_SIZE="0.47031279265780107" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="0.009230099412888701" LOG_CI_START="-0.6644565157028617" LOG_EFFECT_SIZE="-0.32761320814498646" MODIFIED="2010-04-26 10:06:55 -0500" MODIFIED_BY="[Empty name]" ORDER="37" O_E="0.0" SE="0.3957268525215196" STUDY_ID="STD-Sylvester-2010" TOTAL_1="281" TOTAL_2="279" VAR="0.15659974180658856" WEIGHT="51.08907691470417"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-04-26 10:11:46 -0500" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Distant metastases</NAME>
<DICH_OUTCOME CHI2="1.9989329505158435" CI_END="1.2623914204966191" CI_START="0.4534358667389787" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7565801662195057" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.10119403430986565" LOG_CI_START="-0.3434841301937379" LOG_EFFECT_SIZE="-0.12114504794193613" METHOD="MH" MODIFIED="2010-04-26 10:11:46 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5726282377921295" P_Q="0.3931138690658197" P_Z="0.2855574719261713" Q="1.8673122347594326" RANDOM="NO" SCALE="1000.0" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="487" TOTAL_2="495" WEIGHT="100.0" Z="1.0679181026872702">
<NAME>BCG strains</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.479249422900351" CI_START="0.48152410954078434" DF="0" EFFECT_SIZE="1.468627450980392" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.6512052464083614" LOG_CI_START="-0.3173819632053012" LOG_EFFECT_SIZE="0.16691164160153008" MODIFIED="2010-04-26 10:11:44 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.49935753146107387" STUDIES="1" TAU2="0.0" TOTAL_1="102" TOTAL_2="107" WEIGHT="15.300129343220057" Z="0.6755009830657212">
<NAME>Connaught BCG</NAME>
<DICH_DATA CI_END="4.479249422900351" CI_START="0.48152410954078434" EFFECT_SIZE="1.468627450980392" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="5" LOG_CI_END="0.6512052464083614" LOG_CI_START="-0.3173819632053012" LOG_EFFECT_SIZE="0.16691164160153008" MODIFIED="2010-04-26 10:11:44 -0500" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="0.568952921511079" STUDY_ID="STD-Cheng-2005" TOTAL_1="102" TOTAL_2="107" VAR="0.323707426895992" WEIGHT="15.300129343220057"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="8.319099825425518" CI_START="0.014517024142480312" DF="0" EFFECT_SIZE="0.3475177304964539" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="0.9200763356656384" LOG_CI_START="-1.8381224009193708" LOG_EFFECT_SIZE="-0.4590230326268662" MODIFIED="2010-04-26 10:11:46 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.5141692710135073" STUDIES="1" TAU2="0.0" TOTAL_1="46" TOTAL_2="48" WEIGHT="4.604570175810374" Z="0.6523595273173918">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="8.319099825425518" CI_START="0.014517024142480312" EFFECT_SIZE="0.3475177304964539" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9200763356656384" LOG_CI_START="-1.8381224009193708" LOG_EFFECT_SIZE="-0.4590230326268662" MODIFIED="2010-04-26 10:11:46 -0500" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="1.6201795911739783" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="2.6249819076566796" WEIGHT="4.604570175810374"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.148561105522401" CI_END="1.1720888898571677" CI_START="0.35392968209119885" DF="1" EFFECT_SIZE="0.6440784487698479" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="25" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.06896054931907927" LOG_CI_START="-0.45108301400033257" LOG_EFFECT_SIZE="-0.19106123234062664" MODIFIED="2010-04-25 09:51:48 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.699914376237561" P_Z="0.1498219574375063" STUDIES="2" TAU2="0.0" TOTAL_1="339" TOTAL_2="340" WEIGHT="80.09530048096957" Z="1.4401606351561185">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="8.429014092551052" CI_START="0.014556603959138676" EFFECT_SIZE="0.3502824858757062" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9257767799385427" LOG_CI_START="-1.836939933665648" LOG_EFFECT_SIZE="-0.4555815768635528" MODIFIED="2010-04-23 18:55:53 -0500" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.6228334732393923" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="2.633588481866229" WEIGHT="4.585947859291359"/>
<DICH_DATA CI_END="1.218833123040527" CI_START="0.35947525504855393" EFFECT_SIZE="0.6619217081850534" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="24" LOG_CI_END="0.08594424810910109" LOG_CI_START="-0.4443309994834283" LOG_EFFECT_SIZE="-0.1791933756871636" MODIFIED="2010-04-25 09:51:44 -0500" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.3114863053406613" STUDY_ID="STD-Sylvester-2010" TOTAL_1="281" TOTAL_2="279" VAR="0.09702371841477568" WEIGHT="75.5093526216782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2011-03-12 21:02:17 -0600" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Local adverse effects</NAME>
<DICH_OUTCOME CHI2="10.265093710587674" CI_END="2.6527408810485036" CI_START="1.3833507137670118" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.91563853355412" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="140" I2="70.77474317739812" I2_Q="84.40558275656362" ID="CMP-005.01" LOG_CI_END="0.42369483029640637" LOG_CI_START="0.14093229850738553" LOG_EFFECT_SIZE="0.282313564401896" METHOD="MH" MODIFIED="2010-05-08 12:55:11 -0500" MODIFIED_BY="Joey Kwong" NO="1" P_CHI2="0.016442137946737767" P_Q="0.011331671864177828" P_Z="9.089106311871706E-5" Q="6.4125512636318325" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07560679279635424" TOTALS="YES" TOTAL_1="429" TOTAL_2="441" WEIGHT="100.00000000000001" Z="3.913703948496967">
<NAME>Drug-induced cystitis</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.47389361668773566" CI_END="3.310852939825703" CI_START="1.8400287706709166" DF="1" EFFECT_SIZE="2.468210822587827" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="35" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.5199398908575945" LOG_CI_START="0.2648246136866744" LOG_EFFECT_SIZE="0.39238225227213447" MODIFIED="2010-04-23 19:01:50 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49120139268268426" P_Z="1.6489665328166139E-9" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="44.25042780617407" Z="6.029079019919674">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="3.2838683545695835" CI_START="1.614049969141386" EFFECT_SIZE="2.302244039270687" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="23" LOG_CI_END="0.5163857385722599" LOG_CI_START="0.2079169758547269" LOG_EFFECT_SIZE="0.36215135721349334" MODIFIED="2009-11-28 21:50:37 -0600" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.18119607816528055" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.03283201874247846" WEIGHT="25.44100000233991"/>
<DICH_DATA CI_END="4.838690187593373" CI_START="1.7017837922286077" EFFECT_SIZE="2.869565217391304" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="12" LOG_CI_END="0.6847278159242843" LOG_CI_START="0.23090438312426725" LOG_EFFECT_SIZE="0.45781609952427577" MODIFIED="2009-11-28 21:50:37 -0600" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.2665781308889529" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="0.0710638998682477" WEIGHT="18.809427803834165"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4743799497412895" CI_END="1.9258862569560096" CI_START="1.1648275363040759" DF="1" EFFECT_SIZE="1.4977734621403687" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="105" I2="32.174877976638875" ID="CMP-005.01.02" LOG_CI_END="0.2846306340683412" LOG_CI_START="0.06626162873025866" LOG_EFFECT_SIZE="0.17544613139929988" MODIFIED="2010-05-08 12:55:11 -0500" MODIFIED_BY="Joey Kwong" NO="2" P_CHI2="0.2246562311840482" P_Z="0.0016359364997008843" STUDIES="2" TAU2="0.011649047019729726" TOTAL_1="321" TOTAL_2="326" WEIGHT="55.74957219382594" Z="3.1494222198532933">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="2.5797770549765913" CI_START="1.2328068793280378" EFFECT_SIZE="1.7833583208395802" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="23" LOG_CI_END="0.4115821757395547" LOG_CI_START="0.0908950491739175" LOG_EFFECT_SIZE="0.25123861245673607" MODIFIED="2009-11-28 21:51:12 -0600" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.18837320557153345" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.035484464577295205" WEIGHT="24.833563592984927"/>
<DICH_DATA CI_END="1.7146230400372224" CI_START="1.0850002755794654" EFFECT_SIZE="1.3639525178521748" ESTIMABLE="YES" EVENTS_1="111" EVENTS_2="82" LOG_CI_END="0.23416865520886548" LOG_CI_START="0.03542984849111602" LOG_EFFECT_SIZE="0.13479925184999073" MODIFIED="2010-05-08 12:55:11 -0500" MODIFIED_BY="Joey Kwong" ORDER="34" O_E="0.0" SE="0.11674015883896532" STUDY_ID="STD-Sylvester-2010" TOTAL_1="263" TOTAL_2="265" VAR="0.013628264685746853" WEIGHT="30.91600860084101"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1459029622879715" CI_END="2.454400055988167" CI_START="1.4714085751466004" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9003750390965688" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.38994535217572845" LOG_CI_START="0.16773328271640153" LOG_EFFECT_SIZE="0.278839317446065" METHOD="MH" MODIFIED="2011-03-12 21:02:17 -0600" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.7660060946092839" P_Q="0.6081441568962769" P_Z="8.704974109737226E-7" Q="0.26288631983742466" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="429" TOTAL_2="440" WEIGHT="99.99999999999999" Z="4.918859907094751">
<NAME>Haematuria</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.15505380838370747" CI_END="2.9447395463782633" CI_START="0.9410202693922525" DF="1" EFFECT_SIZE="1.6646499936091348" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.4690468887418481" LOG_CI_START="-0.02640102185393343" LOG_EFFECT_SIZE="0.22132293344395731" MODIFIED="2010-04-23 19:02:04 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6937519773561021" P_Z="0.07993177280080904" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="22.074625464841745" Z="1.7510820783612981">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="3.153021413125532" CI_START="0.7259310581042475" EFFECT_SIZE="1.5129032258064516" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.4987269201835788" LOG_CI_START="-0.13910462242195762" LOG_EFFECT_SIZE="0.1798111488808106" MODIFIED="2009-11-28 21:53:54 -0600" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.3746654054435485" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.14037416603617858" WEIGHT="13.703178093082705"/>
<DICH_DATA CI_END="4.746940438237261" CI_START="0.7709671939923182" EFFECT_SIZE="1.9130434782608696" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.6764137824857557" LOG_CI_START="-0.1129641015485665" LOG_EFFECT_SIZE="0.28172484046859453" MODIFIED="2009-11-28 21:53:54 -0600" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.4636844765653058" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="0.21500329380764163" WEIGHT="8.371447371759038"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7202663121399604" CI_END="2.619528454141781" CI_START="1.4772441457036076" DF="1" EFFECT_SIZE="1.9671510042152245" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="55" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.41822312025281294" LOG_CI_START="0.16945227755259656" LOG_EFFECT_SIZE="0.2938376989027047" MODIFIED="2010-05-08 12:56:46 -0500" MODIFIED_BY="Joey Kwong" NO="2" P_CHI2="0.3960565923094651" P_Z="3.655691136206761E-6" STUDIES="2" TAU2="0.0" TOTAL_1="321" TOTAL_2="325" WEIGHT="77.92537453515824" Z="4.630054719422511">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="3.0479008216016252" CI_START="0.711310014668401" EFFECT_SIZE="1.4724137931034482" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.48400083099698543" LOG_CI_START="-0.14794107674484994" LOG_EFFECT_SIZE="0.16802987712606776" MODIFIED="2009-11-28 21:54:44 -0600" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.3712058047704478" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.13779374949527579" WEIGHT="13.89633755657967"/>
<DICH_DATA CI_END="2.8348957054351938" CI_START="1.518099161173638" EFFECT_SIZE="2.074524714828897" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="45" LOG_CI_END="0.45253708602005027" LOG_CI_START="0.1813001402972789" LOG_EFFECT_SIZE="0.3169186131586646" MODIFIED="2010-05-08 12:56:46 -0500" MODIFIED_BY="Joey Kwong" ORDER="35" O_E="0.0" SE="0.15932592456209113" STUDY_ID="STD-Sylvester-2010" TOTAL_1="263" TOTAL_2="264" VAR="0.025384750237565153" WEIGHT="64.02903697857857"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-05-08 12:57:39 -0500" MODIFIED_BY="Joey Kwong" NO="6">
<NAME>Systemic adverse effects</NAME>
<DICH_OUTCOME CHI2="9.566774262138042" CI_END="143.91104852319805" CI_START="2.2546109938409833" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="18.012868514914153" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="5" I2="79.09431177951693" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="2.1580941374283515" LOG_CI_START="0.35307162035942685" LOG_EFFECT_SIZE="1.2555828788938892" METHOD="MH" MODIFIED="2010-05-08 12:57:39 -0500" MODIFIED_BY="Joey Kwong" NO="1" P_CHI2="0.008367647972261194" P_Q="0.7780304216800329" P_Z="0.006396692423239001" Q="0.07946009365422882" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.549659450275008" TOTALS="YES" TOTAL_1="385" TOTAL_2="393" WEIGHT="100.00000000000001" Z="2.7267219095230493">
<NAME>BCG strains</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="54.68193914867008" CI_START="3.336893493769636" DF="0" EFFECT_SIZE="13.508064516129036" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" I2="0.0" ID="CMP-006.01.01" LOG_CI_END="1.737843907260714" LOG_CI_START="0.5233423451605443" LOG_EFFECT_SIZE="1.130593126210629" MODIFIED="2010-04-23 19:06:51 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="2.631556242570996E-4" STUDIES="1" TAU2="0.0" TOTAL_1="62" TOTAL_2="67" WEIGHT="36.75505283886116" Z="3.649104912980946">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="54.68193914867008" CI_START="3.336893493769636" EFFECT_SIZE="13.508064516129032" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="2" LOG_CI_END="1.737843907260714" LOG_CI_START="0.5233423451605443" LOG_EFFECT_SIZE="1.130593126210629" MODIFIED="2009-11-29 01:48:34 -0600" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="0.7134042294573303" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.5089455946076071" WEIGHT="36.75505283886116"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="10.498081629617953" CI_END="3677.418926344548" CI_START="0.2135183893424848" DF="1" EFFECT_SIZE="28.021359104987365" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="3" I2="90.47445013974051" ID="CMP-006.01.02" LOG_CI_END="3.565543106898055" LOG_CI_START="-0.6705647152710799" LOG_EFFECT_SIZE="1.447489195813488" MODIFIED="2010-05-08 12:57:39 -0500" MODIFIED_BY="Joey Kwong" NO="2" P_CHI2="0.0011949898885098564" P_Z="0.18042431653958355" STUDIES="2" TAU2="11.252512139742645" TOTAL_1="323" TOTAL_2="326" WEIGHT="63.24494716113885" Z="1.3394497075631842">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="17.22217626084309" CI_START="1.6056676658537303" EFFECT_SIZE="5.258620689655173" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="3" LOG_CI_END="1.2360880297167747" LOG_CI_START="0.20565566185092257" LOG_EFFECT_SIZE="0.7208718457838486" MODIFIED="2009-11-29 07:43:43 -0600" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="0.6052810736068858" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.3663651780667043" WEIGHT="38.55220869715304"/>
<DICH_DATA CI_END="3028.057219953351" CI_START="11.796672719596199" EFFECT_SIZE="189.0" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="0" LOG_CI_END="3.4811640775899906" LOG_CI_START="1.071759530756498" LOG_EFFECT_SIZE="2.2764618041732443" MODIFIED="2010-05-08 12:57:39 -0500" MODIFIED_BY="Joey Kwong" ORDER="36" O_E="0.0" SE="1.4152961575548524" STUDY_ID="STD-Sylvester-2010" TOTAL_1="265" TOTAL_2="265" VAR="2.0030632135895297" WEIGHT="24.69273846398581"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2010-10-06 10:52:55 -0500" MODIFIED_BY="James Tacklind" NO="7">
<NAME>Delayed or terminated treatment due to adverse effects</NAME>
<DICH_OUTCOME CHI2="6.387021355313287" CI_END="2.039349781155815" CI_START="0.4053333202996561" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9091844796565014" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="33" I2="53.02974840526664" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.3094917206274629" LOG_CI_START="-0.39218769374788265" LOG_EFFECT_SIZE="-0.04134798656020995" METHOD="MH" MODIFIED="2010-10-06 10:52:55 -0500" MODIFIED_BY="James Tacklind" NO="1" P_CHI2="0.09422631024103412" P_Q="0.5639678171283418" P_Z="0.8173223483998854" Q="0.33288082127503077" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3526463367328966" TOTALS="YES" TOTAL_1="431" TOTAL_2="441" WEIGHT="100.0" Z="0.23099028653534665">
<NAME>BCG strains</NAME>
<GROUP_LABEL_1>BCG</GROUP_LABEL_1>
<GROUP_LABEL_2>EPI</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0012336472625157785" CI_END="1.6913554326769176" CI_START="0.23991524136389508" DF="1" EFFECT_SIZE="0.6370101622916371" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" I2="0.0" ID="CMP-007.01.01" LOG_CI_END="0.2282348827188306" LOG_CI_START="-0.6199421612444331" LOG_EFFECT_SIZE="-0.19585363926280128" MODIFIED="2010-04-23 19:08:06 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9719814129732308" P_Z="0.36538299696970067" STUDIES="2" TAU2="0.0" TOTAL_1="108" TOTAL_2="115" WEIGHT="40.013812179825244" Z="0.9051555496067315">
<NAME>Pasteur BCG</NAME>
<DICH_DATA CI_END="2.6007275146193076" CI_START="0.16164931731604576" EFFECT_SIZE="0.6483870967741936" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.41509485235105786" LOG_CI_START="-0.7914261251786254" LOG_EFFECT_SIZE="-0.18816563641378378" MODIFIED="2009-11-29 01:53:32 -0600" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="0.7087163945760959" STUDY_ID="STD-Melekos-1993" TOTAL_1="62" TOTAL_2="67" VAR="0.5022789279409404" WEIGHT="19.871219634992908"/>
<DICH_DATA CI_END="2.4713722531865603" CI_START="0.15861021204767234" EFFECT_SIZE="0.6260869565217392" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.3929381664172591" LOG_CI_START="-0.7996688542619454" LOG_EFFECT_SIZE="-0.20336534392234318" MODIFIED="2009-11-29 01:53:32 -0600" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="0.7005432674469275" STUDY_ID="STD-Melekos-1996a" TOTAL_1="46" TOTAL_2="48" VAR="0.4907608695652174" WEIGHT="20.142592544832336"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.019898888866615" CI_END="4.323149741000751" CI_START="0.2576565709883445" DF="1" EFFECT_SIZE="1.0554088961797714" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" I2="75.12375242149577" ID="CMP-007.01.02" LOG_CI_END="0.6358002784584901" LOG_CI_START="-0.5889587772953225" LOG_EFFECT_SIZE="0.02342075058158382" MODIFIED="2010-05-08 12:58:19 -0500" MODIFIED_BY="Joey Kwong" NO="2" P_CHI2="0.04496649259377039" P_Z="0.9402467218982192" STUDIES="2" TAU2="0.7999207062845061" TOTAL_1="323" TOTAL_2="326" WEIGHT="59.986187820174756" Z="0.07495976847878365">
<NAME>Tice BCG</NAME>
<DICH_DATA CI_END="1.660296536587044" CI_START="0.12236703874923982" EFFECT_SIZE="0.45073891625615764" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.2201856619569381" LOG_CI_START="-0.9123355496504674" LOG_EFFECT_SIZE="-0.3460749438467646" MODIFIED="2009-12-08 07:37:50 -0600" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="0.6652485657686009" STUDY_ID="STD-Melekos-1996b" TOTAL_1="58" TOTAL_2="61" VAR="0.4425556542571805" WEIGHT="21.363638293569423"/>
<DICH_DATA CI_END="3.4563221642459574" CI_START="1.086098480295735" EFFECT_SIZE="1.9375" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.5386142163396609" LOG_CI_START="0.03586920601703491" LOG_EFFECT_SIZE="0.2872417111783479" MODIFIED="2010-05-08 12:58:19 -0500" MODIFIED_BY="Joey Kwong" ORDER="37" O_E="0.0" SE="0.2953149076914477" STUDY_ID="STD-Sylvester-2010" TOTAL_1="265" TOTAL_2="265" VAR="0.08721089470480828" WEIGHT="38.62254952660533"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-06-25 09:41:08 -0500" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="&#26410;&#21629;&#21517;1.JPG" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-06-25 08:48:59 -0500" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-06-25 09:41:08 -0500" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgement on each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-06-25 09:41:08 -0500" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASEAAAGwCAIAAABpRUSqAAARUklEQVR42u3dMY7cxhLG8T2AAgU6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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-12-08 06:28:57 -0600" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-12-08 06:28:57 -0600" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2009-12-08 06:28:57 -0600" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>